http://jnci.oxfordjournals.org/content/103/17/1299.full
<!DOCTYPE html
  PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html
      xmlns="http://www.w3.org/1999/xhtml"
      xml:lang="en"
      lang="en">
   <head>
      <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
      <title>Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis </title>
      <meta name="googlebot" content="NOODP" />
      <meta name="HW.ad-path" content="/cgi/content/full/103/17/1299" />
      <meta content="/jnci/103/17/1299.atom" name="HW.identifier" />
      <meta name="DC.Format" content="text/html" />
      <meta name="DC.Language" content="en" />
      <meta content="Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis"
            name="DC.Title" />
      <meta content="10.1093/jnci/djr242" name="DC.Identifier" />
      <meta content="2011-09-07" name="DC.Date" />
      <meta content="Oxford University Press" name="DC.Publisher" />
      <meta content="Eitan Amir" name="DC.Contributor" />
      <meta content="Bostjan Seruga" name="DC.Contributor" />
      <meta content="Saroj Niraula" name="DC.Contributor" />
      <meta content="Lindsay Carlsson" name="DC.Contributor" />
      <meta content="Alberto Ocaña" name="DC.Contributor" />
      <meta content="Journal of the National Cancer Institute"
            name="citation_journal_title" />
      <meta content="JNCI J Natl Cancer Inst" name="citation_journal_abbrev" />
      <meta content="0027-8874" name="citation_issn" />
      <meta content="1460-2105" name="citation_issn" />
      <meta name="citation_author" content="Eitan Amir" />
      <meta name="citation_author" content="Bostjan Seruga" />
      <meta name="citation_author" content="Saroj Niraula" />
      <meta name="citation_author" content="Lindsay Carlsson" />
      <meta name="citation_author" content="Alberto Ocaña" />
      <meta content="Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis"
            name="citation_title" />
      <meta content="09/07/2011" name="citation_date" />
      <meta content="103" name="citation_volume" />
      <meta content="17" name="citation_issue" />
      <meta content="1299" name="citation_firstpage" />
      <meta content="1309" name="citation_lastpage" />
      <meta content="103/17/1299" name="citation_id" />
      <meta content="103/17/1299" name="citation_id_from_sass_path" />
      <meta content="jnci;103/17/1299" name="citation_mjid" />
      <meta content="10.1093/jnci/djr242" name="citation_doi" />
      <meta content="http://jnci.oxfordjournals.org/content/103/17/1299.abstract"
            name="citation_abstract_html_url" />
      <meta content="http://jnci.oxfordjournals.org/content/103/17/1299.full"
            name="citation_fulltext_html_url" />
      <meta content="http://jnci.oxfordjournals.org/content/103/17/1299.full.pdf"
            name="citation_pdf_url" />
      <meta content="/content/103/17.cover.gif" name="issue_cover_image" />
      <meta content="http://jnci.oxfordjournals.org/content/103/17/1299"
            name="citation_public_url" />
      <meta content="21743022" name="citation_pmid" />
      <meta name="citation_section" content="Review" />
      <meta name="robots" content="noarchive,nofollow" />
      <meta name="googlebot" content="noarchive" />
      <link href="/content/103/17/1292.short" rel="prev" />
      <link href="/content/103/17/1310.short" rel="next" />
      <link rel="stylesheet" type="text/css" media="all" href="/shared/css/hw-global.css" />
      <link rel="stylesheet" type="text/css" media="print" href="/shared/css/hw-print.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/local/css/hw-local-global.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-global.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-ac.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/hw-page-content.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/jquery.fancybox-1.3.4.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/hw-global-colexpand.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-page-content.css" /><script type="text/javascript" id="session-d27448946e1">var callbackToken='5372829EEAE7C7A';</script><script type="text/javascript" id="session-d27448946e3">
                      var subCode='oupjournal_sub';
                    </script><script type="text/javascript">
            var gAuthTimeStamp = '2015-10-27T12:15:18.889-07:00';
            var gSessionId = 'h8yCqF4d1uX4gJCIPBszIA';
            var gAuthzRequired = 'false';
            var gAuthnMethods1 = 'ip ip';
            var gAuthnMethods2 = 'ip,ip';
            var gAuthnIPs = '18.189.59.169,18.189.59.169';
            var gAuthnIndividuals = '';
            var gAuthnInstitutions = '10005282,10072538,10328193,100274300,10082403,05094000,10093227,153074108,10080507,21879000,10095822,10081742,10082405,10004595,10019502,10082401,07635000,10082404,06602000';
            </script><script type="text/javascript" src="/shared/js/jquery-min.js"></script><script type="text/javascript" src="/shared/js/fingerprint.js"></script><script type="text/javascript" src="/shared/js/hw-shared.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-site.js"></script><script type="text/javascript" src="/local/js/local-js-vars.js"></script><script type="text/javascript" src="/shared/js/pages/hw-content.js"></script><script type="text/javascript" src="/shared/js/fancybox/jquery.fancybox-1.3.4.js"></script><script type="text/javascript" src="/shared/js/fancybox/jquery.easing-1.3.pack.js"></script><script type="text/javascript"
              src="/shared/js/fancybox/jquery.mousewheel-3.0.4.pack.js"></script><script type="text/javascript" src="/shared/js/util/content.jquery.addVariantLink.js"></script><script type="text/javascript" src="/shared/js/util/hw-col-expand.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-modalwin-vars.js"></script><script type="text/javascript"
              src="/publisher/js/hw-publisher-article-dynamic-elements.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-content.js"></script><script type="text/javascript" src="/shared/js/util/hw-mathjax.js"></script><script type="text/x-mathjax-config">
          MathJax.Hub.Config({
              tex2jax: {
                inlineMath: [["$","$"],["\\(","\\)"]],
                processClass: "tex2jax_process|mathjax"
              }
            });
          MathJax.Hub.Queue(function() {
            gColTempResize = true;
            fixColHeights(1);
            gColTempResize = false;
          });
       </script><script type="text/javascript"
              src="http://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script><script type="text/javascript">
	    
	    
	    
	    var siqDOI = encodeURIComponent("10.1093/jnci/djr242");
	    var siqIsOpenAccess = encodeURIComponent("");
	    var siqPubDate = encodeURIComponent("20110907");

	    if (siqDOI.length == 0) {
	        siqDOI = "UNKNOWN";
	    }
	    
	    
		
		
	    if (gAuthnIndividuals.length != 0) {
		if (gAuthnInstitutions.length != 0) {
		    authnEntity = encodeURIComponent(gAuthnIndividuals
		        + ',' + gAuthnInstitutions);
		} else {
		    authnEntity = encodeURIComponent(gAuthnIndividuals);
		}
	    } else {
	        authnEntity = encodeURIComponent(gAuthnInstitutions);
	    }

	    var commonString =
		'authSessionId=' + gSessionId + String.fromCharCode(0x26)
		+ 'authzRequired=' + gAuthzRequired + String.fromCharCode(0x26)
		+ 'authentication_method=' + encodeURIComponent(gAuthnMethods2) + String.fromCharCode(0x26)
		+ 'authnIPs=' + gAuthnIPs + String.fromCharCode(0x26)
		+ 'authnInstitutions=' + authnEntity;

		
		
		
		

	    var gPageId = "pageid-content";
	    var gVariant = "full-text";

	    
		// Not completely done
		var eventType = "full-text";
		var accessType;
		if (siqIsOpenAccess == 'true') {
		    accessType = 'SOA';
		} else {
		    accessType = 'subscription';
		}
		    
		var NTPT_PGEXTRA =
		    commonString + String.fromCharCode(0x26)
		    + 'event_type=' + eventType + String.fromCharCode(0x26)
		    + 'publication_date=' + siqPubDate + String.fromCharCode(0x26)
		    + 'access_type=' + accessType + String.fromCharCode(0x26)
		    + 'doi=' + siqDOI ;
		    
		

	    // alert("NTPT_PGEXTRA is " + NTPT_PGEXTRA);
	</script><link rel="stylesheet" type="text/css" media="all" href="/resource/css/hw20.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-header.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-footer.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-sidebars.css" />
      <link type="text/css" media="all" rel="stylesheet" href="/site/resource/jnci_h20.css" />
      <link rel="stylesheet" type="text/css" href="/resource/css/print.css" media="print" /><script type="text/javascript" src="/resource/js/main.js"></script><link rel="stylesheet" type="text/css" media="all"
            href="http://oi-underbar.ifactory.com/underbar/css/pf_oiunderbar.css" />
      <link rel="stylesheet" type="text/css" media="screen"
            href="http://gab.cookie.oup.com/aws-cookie/jquery.fancybox-1.3.4_1.css" /><script type="text/javascript" src="/resource/js/oup_ad_size.js"></script></head>
   <body class="general_page journal jnci">
      <div class="hw-gen-page pagetype-content hw-pub-id-article" id="pageid-content"
           itemscope="itemscope"
           itemtype="http://schema.org/ScholarlyArticle">
         <noscript>
            <p>We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of
               cookies. You can change your cookie settings at any time. <a href="http://global.oup.com/cookiepolicy/">Find out more</a></p>
         </noscript>
         
         
         <p class="hide">
            <a href="#content">Skip Navigation</a>
            
         </p>
         
         
         <div id="secondary_nav">
            <strong id="page_logo" title="Oxford Journals"><a href="http://www.oxfordjournals.org/"><span>Oxford Journals</span></a></strong>
            
            <ul>
               <li id="nav_contact_us" title="Contact Us"><a href="http://www.oxfordjournals.org/contact_us.html"><span>Contact Us</span></a></li>
               <li id="nav_my_basket" title="My Basket"><a href="https://secure.oxfordjournals.org/basket.html"><span>My Basket</span></a></li>
               <li id="nav_my_account" title="My Account"><a href="http://services.oxfordjournals.org/cgi/tslogin?url=http://www.oxfordjournals.org/service/Register"><span>My 
                        
                        Account</span></a></li>
            </ul>
            
         </div>
         
         
         <div id="header">
            
            <h1 id="page_title" title="JNCI J Natl Cancer Inst"><a href="/"><span>
                     JNCI J Natl Cancer Inst
                     </span></a></h1>
            
         </div>
         
         
         <div id="primary_nav">
            
            <ul>
               <li id="nav_about_this_journal" title="About This Journal">
                  <a href="http://www.oxfordjournals.org/jnci/about.html">
                     
                     <span>About This Journal</span>
                     </a>
                  
               </li>
               <li id="nav_contact_this_journal" title="Contact This Journal"><a href="/cgi/feedback/"><span>Contact This Journal</span></a></li>
               <li id="nav_subscriptions" title="Subscriptions">
                  <a href="http://www.oxfordjournals.org/jnci/access_purchase/buy_online.html">
                     
                     <span>Subscriptions</span>
                     </a>
                  
               </li>
               <li id="nav_current_issue" title="Current"><a href="/content/current"><span>View Current Issue (Volume 107 Issue 10 October 2015)</span></a></li>
               <li id="nav_archive" title="Archive"><a href="/content/by/year"><span>Archive</span></a></li>
               <li id="nav_search" title="Search"><a href="/search"><span>Search</span></a></li>
            </ul>
            
         </div>
         
         
         <div id="user_nav">
            
            <div class="header-ac-elements">
               
               <div id="authstring">
                  
                  <ul>
                     <li class="subscr-ref">Institution:  MIT Libraries</li>
                     <li class="no-left-border">
                        <a href="/login?uri=http%3A%2F%2Fjnci.oxfordjournals.org%2Fcontent%2F103%2F17%2F1299.full">
                           Sign In as Personal Subscriber
                           </a>
                        
                     </li>
                  </ul>           
                  
               </div>   
               
            </div>
            
         </div>
         
         
         <ul id="site-breadcrumbs">
            <li class="first"><a href="http://services.oxfordjournals.org/cgi/tslogin?url=http%3A%2F%2Fwww.oxfordjournals.org">Oxford Journals</a></li>
            <li><span class="breadcrumb_subjects"><a href="http://www.oxfordjournals.org/subject/medicine/"
                     class="breadcrumb_subject">Medicine &amp; Health</a></span></li>
            <li><a href="/">JNCI J Natl Cancer Inst</a></li>
            <li><a href="/content/103/17.toc">
                  <span xmlns="" class="volume-value">Volume 103</span>
                  <span xmlns="" class="issue-value"> Issue 17</span></a></li>
            <li>Pp. <span class="slug-pages">
                  1299-1309.
                  </span></li>
         </ul>
         
         
         
         
         <div id="oas_top" class="ad_hidden">
            <iframe id="id_advertframe_top"
                    src="/resource/htmlfiles/advert.html?p=Top&amp;u=jnci.oxfordjournals.org/content/103/17/1299.full"
                    width="0"
                    height="0"
                    frameborder="0"
                    scrolling="no"
                    class="resize_ad"></iframe>
            
         </div>
         
         
         <a name="content"></a>
         
         
         <div id="h20_page"></div>
         
         <div id="content-block">
            <div class="article fulltext-view" itemprop="articleBody"><span class="highwire-journal-article-marker-start"></span><h1 id="article-title-1" itemprop="headline">Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis</h1>
               <div class="contributors">
                  <ol class="contributor-list" id="contrib-group-1">
                     <li class="contributor" id="contrib-1" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Eitan+Amir&amp;sortspec=date&amp;submit=Submit">Eitan Amir</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-2" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Bostjan+Seruga&amp;sortspec=date&amp;submit=Submit">Bostjan Seruga</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-3" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Saroj+Niraula&amp;sortspec=date&amp;submit=Submit">Saroj Niraula</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-4" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Lindsay+Carlsson&amp;sortspec=date&amp;submit=Submit">Lindsay Carlsson</a></span> and 
                     </li>
                     <li class="last" id="contrib-5"><span class="name"><a class="name-search"
                              href="/search?author1=Alberto+Oca%C3%B1a&amp;sortspec=date&amp;submit=Submit">Alberto Ocaña</a></span></li>
                  </ol>
                  <ol class="affiliation-list">
                     <li class="aff"><a id="aff-1" name="aff-1"></a><address><strong>Affiliations of authors:</strong> Department of Medical Oncology and Hematology, Princess Margaret Hospital and the Department of Medicine, University of Toronto,
                           Toronto, ON, Canada (EA, BS, SN, AO); Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia
                           (BS); Department of Ambulatory Care—Breast Site, Princess Margaret Hospital, Toronto, ON, Canada (LC); Medical Oncology Department
                           and AECC unit, Albacete University Hospital, Albacete, Spain (AO)
                        </address>
                     </li>
                  </ol>
                  <ol class="corresp-list">
                     <li class="corresp" id="corresp-1"><strong>Correspondence to:</strong><br /> Eitan Amir, MB ChB, Division of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Ave, Toronto,
                        ON M5G 2M9, Canada (e-mail: <span class="em-link"><span class="em-addr">eitan.amir{at}uhn.on.ca</span></span>).
                     </li>
                  </ol>
                  <ul class="history-list">
                     <li xmlns:hwp="http://schema.highwire.org/Journal" class="received"
                         hwp:start="2010-12-20"><span class="received-label">Received </span>December 20, 2010.
                     </li>
                     <li xmlns:hwp="http://schema.highwire.org/Journal" class="rev-recd"
                         hwp:start="2011-05-24"><span class="rev-recd-label">Revision received </span>May 24, 2011.
                     </li>
                     <li xmlns:hwp="http://schema.highwire.org/Journal" class="accepted"
                         hwp:start="2011-06-01"><span class="accepted-label">Accepted </span>June 1, 2011.
                     </li>
                  </ul>
               </div>
               <div class="section abstract" id="abstract-1" itemprop="description">
                  <div class="section-nav">
                     <div class="nav-placeholder"> </div><a href="#sec-11" title="Methods" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Abstract</h2>
                  <div id="sec-1" class="subsection">
                     <p id="p-1"><strong>Background</strong> Aromatase inhibitors are associated with consistent improvements in disease-free survival but not in overall survival. We
                        conducted a literature-based meta-analysis of randomized trials to examine whether the relative toxicity of aromatase inhibitors
                        compared with tamoxifen may explain this finding.
                     </p>
                  </div>
                  <div id="sec-2" class="subsection">
                     <p id="p-2"><strong>Methods</strong> We conducted a systematic review to identify randomized controlled trials that compared aromatase inhibitors and tamoxifen
                        as primary adjuvant endocrine therapy in postmenopausal women by searching MEDLINE, EMBASE, and databases of the American
                        Society of Clinical Oncology and San Antonio Breast Cancer Symposium. Odds ratios (ORs), 95% confidence intervals (CIs), absolute
                        risks, and the number needed to harm associated with one adverse event were computed for prespecified serious adverse events
                        including cardiovascular disease, cerebrovascular disease, bone fractures, thromboembolic events, endometrial carcinoma and
                        other second cancers not including new breast cancer. All statistical tests were two-sided.
                     </p>
                  </div>
                  <div id="sec-3" class="subsection">
                     <p id="p-3"><strong>Results</strong> Seven trials enrolling 30 023 patients met the inclusion criteria. Longer duration of aromatase inhibitor use was associated
                        with increased odds of developing cardiovascular disease (OR = 1.26, 95% CI = 1.10 to 1.43, <em>P</em> &lt; .001; number needed to harm = 132) and bone fractures (OR = 1.47, 95% CI = 1.34 to 1.61, <em>P</em> &lt; .001; number needed to harm = 46), but a decreased odds of venous thrombosis (OR = 0.55, 95% CI = 0.46 to 0.64, <em>P</em> &lt; .001; number needed to harm = 79) and endometrial carcinoma (OR = 0.34, 95% CI = 0.22 to 0.53, <em>P</em> &lt; .001; number needed to harm = 258). Five years of aromatase inhibitors was associated with a non-statistically significant
                        increased odds of death without recurrence compared with 5 years of tamoxifen alone or tamoxifen for 2–3 years followed by
                        an aromatase inhibitor for 2–3 years (OR = 1.11, 95% CI = 0.98 to 1.26, <em>P</em> = .09).
                     </p>
                  </div>
                  <div id="sec-4" class="subsection">
                     <p id="p-4"><strong>Conclusions</strong> The cumulative toxicity of aromatase inhibitors when used as up-front treatment may explain the lack of overall survival
                        benefit despite improvements in disease-free survival. Switching from tamoxifen to aromatase inhibitors reduces this toxicity
                        and is likely the best balance between efficacy and toxicity.
                     </p>
                  </div>
               </div>
               <p id="p-5">
                  <div class="boxed-text" id="boxed-text-1">
                     <div id="sec-5" class="subsection">
                        <h4>CONTEXT AND CAVEATS</h4>
                        <div id="sec-6" class="subsection">
                           <h5>Prior knowledge</h5>
                           <p id="p-6">Large randomized trials comparing an aromatase inhibitor with 5 years of tamoxifen as adjuvant endocrine therapy for postmenopausal
                              breast cancer have shown that aromatase inhibitors are associated with consistent improvements in disease-free survival but
                              not in overall survival. Differences in the toxicity of aromatase inhibitors and tamoxifen may explain these findings.
                           </p>
                        </div>
                        <div id="sec-7" class="subsection">
                           <h5>Study design</h5>
                           <p id="p-7">Systematic review and literature-based meta-analysis of seven randomized controlled trials that compared aromatase inhibitors
                              with tamoxifen as primary adjuvant endocrine therapy for early-stage postmenopausal breast cancer. Absolute risks of six adverse
                              events were computed separately for patients who received aromatase inhibitors and tamoxifen.
                           </p>
                        </div>
                        <div id="sec-8" class="subsection">
                           <h5>Contribution</h5>
                           <p id="p-8">Compared with tamoxifen, the use of aromatase inhibitors in postmenopausal women with early-stage breast cancer increased
                              the odds of developing cardiovascular disease and bone fractures and decreased the odds of developing venous thrombosis and
                              endometrial carcinoma. There were no statistically significant differences in the odds of cerebrovascular disease, other second
                              cancers, or death without breast cancer recurrence between treatment strategies. There were fewer deaths without recurrence
                              in those treated with switching from tamoxifen to aromatase inhibitors compared with those treated with either tamoxifen alone
                              or up-front aromatase inhibitors.
                           </p>
                        </div>
                        <div id="sec-9" class="subsection">
                           <h5>Implication</h5>
                           <p id="p-9">The cumulative toxicity of aromatase inhibitors when used as up-front treatment may explain the lack of overall survival benefit
                              despite improvements in disease-free survival.
                           </p>
                        </div>
                        <div id="sec-10" class="subsection">
                           <h5>Limitations</h5>
                           <p id="p-10">The meta-analysis was based on study-level adverse events that were reported by the investigator, not on individual patient
                              data. No data on adverse events after breast cancer recurrence were available nor was information on potentially confounding
                              baseline host factors or the use of concurrent medications. All grades of toxicity were included in the analysis.
                           </p>
                           <p id="p-11"><em>From the Editors</em></p>
                        </div>
                     </div>
                  </div>
               </p>
               <p id="p-12">The development of aromatase inhibitors has provided an alternative form of adjuvant endocrine therapy for postmenopausal
                  women with breast cancer (<a id="xref-ref-1-1" class="xref-bibr" href="#ref-1">1</a>). Several large randomized trials have assessed the benefit of the third-generation aromatase inhibitors anastrozole, letrozole,
                  and exemestane compared with 5 years of tamoxifen (<a id="xref-ref-2-1" class="xref-bibr" href="#ref-2">2</a>–<a id="xref-ref-5-1" class="xref-bibr" href="#ref-5">5</a>). These trials have shown that aromatase inhibitors are associated with reduced recurrence rates and improved disease-free
                  survival but have not demonstrated a statistically significant improvement in overall survival. Despite their large size,
                  the individual trials had limited statistical power to detect small (but potentially important) differences in overall survival
                  in the absence of extended follow-up. A meta-analysis of the randomized trials by the Oxford Early Breast Cancer Trialists’
                  Collaborative Group that had greater statistical power confirmed that use of aromatase inhibitors was associated with improved
                  disease-free survival and also showed a statistically significant albeit modest improvement in overall survival only for patients
                  who took aromatase inhibitors for 2–3 years after treatment with tamoxifen for 2–3 years (<a id="xref-ref-6-1" class="xref-bibr" href="#ref-6">6</a>). No overall survival benefit was seen in those who received aromatase inhibitors as initial (ie, up-front) therapy.
               </p>
               <p id="p-13">The lack of an overall survival benefit with aromatase inhibitors despite improvements in disease-free survival is unexpected.
                  We therefore hypothesized that the relative toxicity of aromatase inhibitors compared with tamoxifen (<a id="xref-ref-7-1" class="xref-bibr" href="#ref-7">7</a>,<a id="xref-ref-8-1" class="xref-bibr" href="#ref-8">8</a>) may explain these findings. Some have suggested that aromatase inhibitors should be used for 2–3 years after or before tamoxifen
                  (ie, in a switching strategy) to maximize benefits and offset the toxic effects (<a id="xref-ref-8-2" class="xref-bibr" href="#ref-8">8</a>,<a id="xref-ref-9-1" class="xref-bibr" href="#ref-9">9</a>). Unfortunately, most individual trials that have assessed aromatase inhibitors vs tamoxifen had suboptimal statistical power
                  and/or duration of follow-up to detect differences in toxicities between these strategies. Furthermore, meta-analyses conducted
                  by the Oxford Overview have tended to assess efficacy, not toxicity. This study was designed to evaluate and compare serious
                  and/or life-threatening adverse events reported in randomized trials comparing different adjuvant endocrine therapy strategies
                  in postmenopausal women with early-stage breast cancer by using a meta-analysis.
               </p>
               <div class="section methods" id="sec-11">
                  <div class="section-nav"><a href="#abstract-1" title="Abstract" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-16" title="Results" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Methods</h2>
                  <div id="sec-12" class="subsection">
                     <h3>Search Strategy</h3>
                     <p id="p-14">Relevant trials were identified using a computerized search of the following databases: MEDLINE (host: OVID), 1996–April week
                        2, 2010; EMBASE (host: OVID), 1980–2010 week 16; American Society of Clinical Oncology Annual Meetings, 2000–2009; and San
                        Antonio Breast Cancer Symposium Annual Meetings, 2000–2009. The search was restricted to English language articles. The terms
                        “adjuvant,” “aromatase inhibitor,” and “tamoxifen” and “breast cancer” and similar terms were cross-searched by using the
                        following search algorithm: ((aromatase inhibitor OR anastrozole OR letrozole OR exemestane) AND (tamoxifen) AND (adjuvant)
                        AND (Breast neoplasm MeSH OR ((breast OR mammary) AND (carcinoma OR malignan* OR neoplasm OR tumor)))) AND (randomized controlled
                        trial [pt]OR controlled clinical trial [pt]OR randomized controlled trial [mh]OR double-blind method [mh] OR single-blind
                        method [mh] OR clinical trial [pt] OR clinical trials [mh] OR (“clinical trial”) [tw] OR singl* [tw] OR doubl* [tw] OR trebl*
                        [tw] OR tripl* [tw] AND (mask* [tw] OR blind* [tw])) OR comparative study [mh] OR evaluation studies [mh] OR follow-up studies
                        [mh] OR prospective studies [mh] OR control* [tw] OR prospective* [tw] OR volunteer* [tw] NOT (animals [mh] NOT humans [mh]).
                        Included studies were randomized phase III clinical trials that compared aromatase inhibitors with tamoxifen as initial adjuvant
                        therapy in postmenopausal women with early-stage breast cancer. Only trials that had treatment durations of 5 years in total
                        were included. Trials that had treatment durations longer than 5 years (extended adjuvant) were excluded, as were trials conducted
                        in pre- or perimenopausal women. Published articles and abstracts presented at annual meetings were included in a meta-analysis.
                        All data were from intent-to-treat analyses. The primary objective of this study was to assess toxicity; therefore, we included
                        data from all randomly assigned patients regardless of their hormone receptor status.
                     </p>
                  </div>
                  <div id="sec-13" class="subsection">
                     <h3>Data Extraction</h3>
                     <p id="p-15">Data on prespecified serious or potentially life-threatening adverse events of any grade as defined by the individual trials
                        were extracted. In addition, we assessed information on deaths without breast cancer recurrence. Data on adverse events and
                        death without recurrence were extracted from the primary publications and from any associated online appendices by two authors
                        (EA and BS) using a standardized data extraction form. Discrepancies were resolved by consensus. Six adverse events were prespecified
                        in this analysis as follows: cardiovascular disease (including myocardial infarction, angina, and cardiac failure), cerebrovascular
                        disease (including cerebrovascular accident and transient ischemic attack), venous thrombosis (defined as any venous thromoembolic
                        episode), bone fracture (any), endometrial carcinoma alone, and other secondary cancers (defined as any invasive cancer excluding
                        endometrial carcinoma and contralateral breast cancer). Hypercholesterolemia was assessed in a preplanned exploratory analysis
                        because it is a well-documented adverse effect of aromatase inhibitors and is associated with both cardiovascular and cerebrovascular
                        disease. All grades of hypercholesterolemia were included in the meta-analysis. Adverse events such as hot flashes or arthralgia
                        were excluded.
                     </p>
                  </div>
                  <div id="sec-14" class="subsection">
                     <h3>Data Synthesis</h3>
                     <p id="p-16">The meta-analysis was carried out in three treatment cohorts: 1) 5 years of an aromatase inhibitor vs 5 years of tamoxifen
                        (ie, up-front treatment with aromatase inhibitor vs tamoxifen), 2) tamoxifen for 2–3 followed by an aromatase inhibitor for
                        2–3 years vs 5 years of tamoxifen (ie, switching vs tamoxifen), and 3) tamoxifen for 2–3 years followed by an aromatase inhibitor
                        for 2–3 years vs 5 years of an aromatase inhibitor (ie, switching vs aromatase inhibitor). In general, the aromatase inhibitor
                        group included trial arms that received aromatase inhibitors alone or aromatase inhibitors for longer durations compared with
                        the other intervention arm, and the tamoxifen group included trial arms that received tamoxifen alone or aromatase inhibitors
                        for shorter durations compared with the other treatment arm.
                     </p>
                  </div>
                  <div id="sec-15" class="subsection">
                     <h3>Statistical Analysis</h3>
                     <p id="p-17">The relative frequency of an individual adverse event per person was expressed as an odds ratio (OR) and a 95% confidence
                        interval (CI). Initial analyses were conducted separately for each treatment cohort described above. We also analyzed the
                        pooled data for all three cohorts. All data were analyzed using RevMan 5 analysis software (The Cochrane Collaboration, Copenhagen,
                        Denmark). Pooled estimates of odd ratios were computed using generic inverse variance (<a id="xref-ref-10-1" class="xref-bibr" href="#ref-10">10</a>) and a fixed-effects model (<a id="xref-ref-11-1" class="xref-bibr" href="#ref-11">11</a>). Studies were weighted by their individual SE, thereby accounting for differences in both sample size and intrastudy heterogeneity.
                        Data were not adjusted for different durations of follow-up between studies. Differences between the three cohorts (subgroups)
                        were assessed using methods described by Deeks et al. (<a id="xref-ref-12-1" class="xref-bibr" href="#ref-12">12</a>). Absolute risks of each adverse event were calculated as the number of events per person over the follow-up period of the
                        individual trial. The difference in absolute risk between the aromatase inhibitor group and the tamoxifen group was also presented
                        as the number needed to harm, which quantifies the number of patients who would need to be treated with a particular intervention
                        to cause an adverse event in one patient who would not otherwise have experienced the adverse event. Positive values indicate
                        higher absolute risks in the aromatase inhibitor group, whereas negative values indicate higher absolute risks in the tamoxifen
                        group. We conducted a post hoc sensitivity analysis for the switching vs tamoxifen cohort to adjust for better survival in
                        the aromatase inhibitor group vs tamoxifen group. We adjusted for an absolute difference in overall mortality of 2.2% (<a id="xref-ref-6-2" class="xref-bibr" href="#ref-6">6</a>). No such analyses were carried out for the other two cohorts because meta-analyses have not shown survival differences in
                        the included trials (<a id="xref-ref-6-3" class="xref-bibr" href="#ref-6">6</a>). All statistical tests were two-sided, and statistical significance was defined as <em>P</em> less than .05.
                     </p>
                  </div>
               </div>
               <div class="section results" id="sec-16">
                  <div class="section-nav"><a href="#sec-11" title="Methods" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-25" title="Discussion" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Results</h2>
                  <p id="p-18">We identified 377 potentially relevant articles in the primary literature search, of which seven were reports of randomized
                     phase III trials enrolling 30 023 patients who met the inclusion criteria. Articles were excluded if they did not compare
                     aromatase inhibitors to tamoxifen (n = 172), were review articles (n = 169), were cost-effectiveness analyses (n = 18), or
                     were early analyses of included trials (n = 9). Two trials contributed data to the analysis of up-front aromatase inhibitors
                     vs up-front tamoxifen: Arimidex, Tamoxifen, Alone or in Combination (ATAC; n = 6241 patients) (<a id="xref-ref-5-2" class="xref-bibr" href="#ref-5">5</a>) and Breast International Group 01-98 (BIG 1-98; n = 4922 patients) (<a id="xref-ref-3-1" class="xref-bibr" href="#ref-3">3</a>). Four publications comprising five trials contributed data to the analysis of switching from tamoxifen to aromatase inhibitors
                     vs tamoxifen: A combined analysis of the Austrian Breast and Colorectal Cancer Study Group trial 8 and the German Adjuvant
                     Breast Cancer Group/Arimidex–Nolvadex (ABCSG8/ARNO 95; n = 3226 patients) (<a id="xref-ref-4-1" class="xref-bibr" href="#ref-4">4</a>), the Intergroup Exemestane Study (IES; n = 4724 patients) (<a id="xref-ref-13-1" class="xref-bibr" href="#ref-13">13</a>), the Italian Tamoxifen Anastrozole trial (ITA; n = 448 patients) (<a id="xref-ref-2-2" class="xref-bibr" href="#ref-2">2</a>), and the National Surgical Adjuvant Study Breast Cancer 03 trial (N-SAS BC03; n = 696 patients) (<a id="xref-ref-14-1" class="xref-bibr" href="#ref-14">14</a>). The sequencing arms of BIG 1-98 were not included because there were different follow-up times for the different arms of
                     the trial. One trial—the Tamoxifen Exemestane Adjuvant Multinational trial (TEAM, n = 9766 patients) (<a id="xref-ref-15-1" class="xref-bibr" href="#ref-15">15</a>)—provided data for the analysis of switching from tamoxifen to aromatase inhibitors vs aromatase inhibitors. The study designs
                     and characteristics of the included studies are shown in <a id="xref-fig-1-1" class="xref-fig" href="#F1">Figure 1</a> and <a id="xref-table-wrap-1-1" class="xref-table" href="#T1">Table 1</a>, respectively.
                  </p>
                  <div class="table pos-float" id="T1">
                     <div class="table-inline">
                        <div class="callout"><span>View this table:</span><ul class="callout-links">
                              <li><a href="1299/T1.expansion.html">In this window</a></li>
                              <li><a class="in-nw" href="1299/T1.expansion.html">In a new window</a></li>
                           </ul>
                        </div>
                     </div>
                     <div class="table-caption"><span class="table-label">Table 1</span> 
                        <p id="p-19" class="first-child">Characteristics of included studies<sup>*</sup></p>
                        <div class="sb-div caption-clear"></div>
                     </div>
                  </div>
                  <div id="F1" class="fig pos-float odd">
                     <div class="fig-inline"><a href="1299/F1.expansion.html"><img alt="Figure 1" src="1299/F1.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                              <li><a href="1299/F1.expansion.html">In this window</a></li>
                              <li><a class="in-nw" href="1299/F1.expansion.html">In a new window</a></li>
                           </ul>
                           <ul class="fig-services">
                              <li class="ppt-link"><a href="/powerpoint/103/17/1299/F1">Download as PowerPoint Slide</a></li>
                           </ul>
                        </div>
                     </div>
                     <div class="fig-caption"><span class="fig-label">Figure 1</span> 
                        <p id="p-23" class="first-child">Designs of included studies. ATAC = Anastrozole, Tamoxifen alone or in combination (<a id="xref-ref-5-4" class="xref-bibr" href="#ref-5">5</a>); BIG 1-98 = Breast International Group 01-98 (<a id="xref-ref-3-3" class="xref-bibr" href="#ref-3">3</a>); ABCSG8 = Austrian Breast Cancer Study Group VIII (<a id="xref-ref-4-3" class="xref-bibr" href="#ref-4">4</a>); ARNO = German Adjuvant Breast Cancer Group/Arimidex–Nolvadex (<a id="xref-ref-4-4" class="xref-bibr" href="#ref-4">4</a>); ITA = Italian Tamoxifen Anastrozole Trial (<a id="xref-ref-2-4" class="xref-bibr" href="#ref-2">2</a>); N-SAS BC04 = National Surgical Adjuvant Study Breast Cancer 03 trial (<a id="xref-ref-14-3" class="xref-bibr" href="#ref-14">14</a>); TEAM = Tamoxifen Exemestane Adjuvant Multinational Trial (<a id="xref-ref-15-3" class="xref-bibr" href="#ref-15">15</a>); R = randomization.
                        </p>
                        <div class="sb-div caption-clear"></div>
                     </div>
                  </div>
                  <p id="p-24">The numbers of adverse events, follow-up time, and the number of evaluable patients for each adverse event are shown in <a href="http://jnci.oxfordjournals.org/cgi/content/full/djr242/dc1">Supplementary Table 1</a> (available online). <a id="xref-table-wrap-2-1" class="xref-table" href="#T2">Table 2</a> presents the difference in absolute risk for each adverse event between the aromatase inhibitor group and the tamoxifen group
                     and the number needed to harm.
                  </p>
                  <div class="table pos-float" id="T2">
                     <div class="table-inline">
                        <div class="callout"><span>View this table:</span><ul class="callout-links">
                              <li><a href="1299/T2.expansion.html">In this window</a></li>
                              <li><a class="in-nw" href="1299/T2.expansion.html">In a new window</a></li>
                           </ul>
                        </div>
                     </div>
                     <div class="table-caption"><span class="table-label">Table 2</span> 
                        <p id="p-25" class="first-child">Absolute differences and number needed to harm associated with one adverse event of each type<sup>*</sup></p>
                        <div class="sb-div caption-clear"></div>
                     </div>
                  </div>
                  <div id="sec-17" class="subsection">
                     <h3>Cardiovascular Disease</h3>
                     <p id="p-28">Longer durations of aromatase inhibitor use were associated with increased odds of cardiovascular disease compared with tamoxifen
                        use. Combined analysis of the two trials that evaluated up-front aromatase inhibitors vs up-front tamoxifen (<a id="xref-ref-3-5" class="xref-bibr" href="#ref-3">3</a>,<a id="xref-ref-5-6" class="xref-bibr" href="#ref-5">5</a>) showed a statistically significant association between aromatase inhibitor use and cardiovascular disease (OR = 1.30, 95%
                        CI = 1.06 to 1.61, <em>P</em> = .01) (<a id="xref-fig-2-1" class="xref-fig" href="#F2">Figure 2, A</a>). Combined analysis of trials that evaluated switching vs up-front tamoxifen (<a id="xref-ref-2-6" class="xref-bibr" href="#ref-2">2</a>,<a id="xref-ref-4-6" class="xref-bibr" href="#ref-4">4</a>,<a id="xref-ref-13-4" class="xref-bibr" href="#ref-13">13</a>,<a id="xref-ref-14-5" class="xref-bibr" href="#ref-14">14</a>) showed a non-statistically significant association between aromatase inhibitor use and cardiovascular disease (OR = 1.15,
                        95% CI = 0.93 to 1.41, <em>P</em> = .20) (<a id="xref-fig-2-2" class="xref-fig" href="#F2">Figure 2, A</a>). After adjustment for differential survival between the aromatase inhibitor group and the tamoxifen group, the odds ratio
                        was 1.12 (95% CI = 0.92 to 1.35, <em>P</em> = .26). Finally, the one trial (<a id="xref-ref-15-5" class="xref-bibr" href="#ref-15">15</a>) that evaluated switching vs up-front aromatase inhibitors showed a statistically significant association between aromatase
                        inhibitor use and cardiovascular disease (OR = 1.37, 95% CI = 1.05 to 1.79, <em>P</em> = .02) (<a id="xref-fig-2-3" class="xref-fig" href="#F2">Figure 2, A</a>). A pooled analysis of the data for all three cohorts showed that longer duration of aromatase inhibitor use was associated
                        with a statistically significant increase in the odds of developing cardiovascular disease compared with tamoxifen alone or
                        shorter duration of aromatase inhibitor use (OR = 1.26, 95% CI = 1.10 to 1.43, <em>P</em> &lt; .001) (<a id="xref-fig-2-4" class="xref-fig" href="#F2">Figure 2, A</a>). Adjustment for differential survival between the aromatase inhibitor group and the tamoxifen group did not change the pooled
                        odds ratio for all cohorts (data not shown). In absolute terms, 4.2% of patients in the aromatase inhibitor group and 3.4%
                        of patients in the tamoxifen group suffered a cardiovascular event (difference in absolute risk = 0.8%, number needed to harm
                        = 132) (<a id="xref-table-wrap-2-2" class="xref-table" href="#T2">Table 2</a> and <a href="http://jnci.oxfordjournals.org/cgi/content/full/djr242/dc1">Supplementary Table 1</a>, available online). Increased odds of cardiovascular events in the aromatase inhibitor group vs tamoxifen group were seen
                        in all treatment cohorts, although the magnitude was numerically, but not statistically significantly lower for the treatment
                        cohort where aromatase inhibitors were administered after 2–3 years of treatment with tamoxifen (ORs of 1.15 vs 1.30 and 1.37,
                        test of subgroup differences, <em>P</em> = .53).
                     </p>
                     <div id="F2" class="fig pos-float odd">
                        <div class="fig-inline"><a href="1299/F2.expansion.html"><img alt="Figure 2" src="1299/F2.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                                 <li><a href="1299/F2.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="1299/F2.expansion.html">In a new window</a></li>
                              </ul>
                              <ul class="fig-services">
                                 <li class="ppt-link"><a href="/powerpoint/103/17/1299/F2">Download as PowerPoint Slide</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="fig-caption"><span class="fig-label">Figure 2</span> 
                           <p id="p-29" class="first-child">Forest plots of odds ratios for adverse events. <strong>A</strong>) Cardiovascular events. <strong>B</strong>) Cerebrovascular events. <strong>C</strong>) Venous thrombosis. <strong>D</strong>) Bone fractures. <strong>E</strong>) Endometrial carcinoma. <strong>F</strong>) Other second cancers. Odds ratios for each trial are represented by the <strong>squares</strong>, the <strong>size of the square</strong> represents the weight of the trial in the meta-analysis, and the <strong>horizontal line</strong> crossing the square represents the 95% confidence interval. The <strong>diamonds</strong> represent the estimated pooled effect based for each cohort individually (labeled subtotal) and for all cohorts together
                              (labeled total). Test of subgroup differences relates to the test of heterogeneity between the three treatment cohorts as
                              defined by Deeks et al. (<a id="xref-ref-12-2" class="xref-bibr" href="#ref-12">12</a>). All <em>P</em> values are two-sided. ATAC = Anastrozole, Tamoxifen alone or in combination (<a id="xref-ref-5-7" class="xref-bibr" href="#ref-5">5</a>); BIG 1-98 = Breast International Group 01-98 (<a id="xref-ref-3-6" class="xref-bibr" href="#ref-3">3</a>); ABCSG8 = Austrian Breast Cancer Study Group VIII (<a id="xref-ref-4-7" class="xref-bibr" href="#ref-4">4</a>); ARNO = German Adjuvant Breast Cancer Group/Arimidex–Nolvadex (<a id="xref-ref-4-8" class="xref-bibr" href="#ref-4">4</a>); ITA = Italian Tamoxifen Anastrozole Trial (<a id="xref-ref-2-7" class="xref-bibr" href="#ref-2">2</a>); N-SAS BC04 = National Surgical Adjuvant Study Breast Cancer 03 trial (<a id="xref-ref-14-6" class="xref-bibr" href="#ref-14">14</a>); TEAM = Tamoxifen Exemestane Adjuvant Multinational Trial (<a id="xref-ref-15-6" class="xref-bibr" href="#ref-15">15</a>); AI = aromatase inhibitor; CI = confidence interval; OR = odds ratio.
                           </p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                  </div>
                  <div id="sec-18" class="subsection">
                     <h3>Cerebrovascular Disease</h3>
                     <p id="p-30">Neither the individual studies nor the pooled data showed any statistically significant difference in the odds of cerebrovascular
                        disease between the two treatment groups (OR = 1.01, 95% CI = 0.81 to 1.26, <em>P</em> = .93) (<a id="xref-fig-2-5" class="xref-fig" href="#F2">Figure 2, B</a>). Adjustment for differential survival between the aromatase inhibitor group and the tamoxifen group did not change the pooled
                        odds ratio for all cohorts (data not shown). Cerebrovascular disease was an uncommon adverse event: it occurred in 1.4% of
                        patients in the aromatase inhibitor group and in 1.5% of patients in the tamoxifen group (difference in absolute risk = −0.1%,
                        number needed to harm = −974) (<a id="xref-table-wrap-2-3" class="xref-table" href="#T2">Table 2</a> and <a href="http://jnci.oxfordjournals.org/cgi/content/full/djr242/dc1">Supplementary Table 1</a>, available online).
                     </p>
                  </div>
                  <div id="sec-19" class="subsection">
                     <h3>Venous Thrombosis</h3>
                     <p id="p-31">Longer durations of aromatase inhibitor use were associated with decreased odds of venous thrombosis compared with tamoxifen.
                        A pooled analysis of the data for all three cohorts revealed a 45% reduction in the relative odds of venous thrombosis for
                        the aromatase inhibitor group compared with the tamoxifen group (OR = 0.55, 95% CI = 0.46 to 0.64, <em>P</em> &lt; .001) (<a id="xref-fig-2-6" class="xref-fig" href="#F2">Figure 2, C</a>). Adjustment for differential survival between the aromatase inhibitor group and the tamoxifen group did not change the pooled
                        odds ratio for all cohorts (data not shown). The incidence of thrombosis was 1.6% and 2.8% in the aromatase inhibitor and
                        tamoxifen groups, respectively (difference in absolute risk = −1.3%, number needed to harm = −79) (<a id="xref-table-wrap-2-4" class="xref-table" href="#T2">Table 2</a> and <a href="http://jnci.oxfordjournals.org/cgi/content/full/djr242/dc1">Supplementary Table 1</a>, available online). The test of subgroup differences for up-front aromatase inhibitors vs switching from tamoxifen to aromatase
                        inhibitors was not statistically significant (<em>P</em> = .67), suggesting that the relative harm of 2–3 years of tamoxifen was not reduced by switching to aromatase inhibitors.
                     </p>
                  </div>
                  <div id="sec-20" class="subsection">
                     <h3>Bone Fractures</h3>
                     <p id="p-32">Longer durations of aromatase inhibitor use were associated with increased odds of bone fractures compared with tamoxifen
                        use. A pooled analysis of the data for all three cohorts showed that a longer duration of aromatase inhibitor use was associated
                        with a 47% increase in the odds of bone fractures compared with tamoxifen (OR = 1.47, 95% CI = 1.34 to 1.61, <em>P</em> &lt; .001) (<a id="xref-fig-2-7" class="xref-fig" href="#F2">Figure 2, D</a>). After adjustment for differential survival between the aromatase inhibitor group and the tamoxifen group, the odds ratio
                        decreased slightly to 1.45 (95% CI = 1.33 to 1.60) but remained statistically significant (<em>P</em> &lt; .001). In absolute terms, fracture incidence was 7.5% and 5.2% in the aromatase inhibitor and tamoxifen groups, respectively
                        (difference in absolute risk = 2.2%, number needed to harm = 46) (<a id="xref-table-wrap-2-5" class="xref-table" href="#T2">Table 2</a> and <a href="http://jnci.oxfordjournals.org/cgi/content/full/djr242/dc1">Supplementary Table 1</a>, available online). The test of subgroup differences for up-front aromatase inhibitors vs switching from tamoxifen to aromatase
                        inhibitors was not statistically significant (<em>P</em> = .97), suggesting that there was no difference in the relative harm of aromatase inhibitors between up-front use of aromatase
                        inhibitors and use of aromatase inhibitors after switching from tamoxifen.
                     </p>
                  </div>
                  <div id="sec-21" class="subsection">
                     <h3>Endometrial Carcinoma</h3>
                     <p id="p-33">Analysis of the pooled data showed that longer duration of aromatase inhibitor use was associated with a 66% reduction in
                        the relative odds of endometrial carcinoma compared with tamoxifen (OR = 0.34, 95% CI = 0.22 to 0.53, <em>P</em> &lt; .001) (<a id="xref-fig-2-8" class="xref-fig" href="#F2">Figure 2, E</a>). Adjustment for differential survival between the aromatase inhibitor group and the tamoxifen group did not change the pooled
                        odds ratio for any of the cohorts. Endometrial carcinoma was a very rare event: it occurred in 0.1% of the aromatase inhibitor
                        group and in 0.5% of the tamoxifen group (difference in absolute risk = −0.4%, number needed to harm = −258) (<a id="xref-table-wrap-2-6" class="xref-table" href="#T2">Table 2</a> and <a href="http://jnci.oxfordjournals.org/cgi/content/full/djr242/dc1">Supplementary Table 1</a>, available online). The test of subgroup differences for up-front aromatase inhibitors vs switching from tamoxifen to aromatase
                        inhibitors was not statistically significant (<em>P</em> = .35).
                     </p>
                  </div>
                  <div id="sec-22" class="subsection">
                     <h3>Other Second Cancers</h3>
                     <p id="p-34">Analysis of the pooled data showed no statistically significant difference in the odds of developing other second cancers
                        between the aromatase inhibitor group and the tamoxifen group (OR = 0.98, 95% CI = 0.85 to 1.14, <em>P</em> = .83), and adjustment for differential survival between the groups did not change the pooled odds ratio for any of the cohorts.
                        The absolute rates of other cancers were 4.7% for aromatase inhibitor–treated patients and 4.8% for those receiving tamoxifen
                        alone (<a id="xref-table-wrap-2-7" class="xref-table" href="#T2">Table 2</a>). The test of subgroup difference for up-front aromatase inhibitors vs switching from tamoxifen to aromatase inhibitors was
                        statistically significant (<em>P</em> = .02), suggesting that switching from tamoxifen to aromatase inhibitors may decrease the odds of second cancers.
                     </p>
                  </div>
                  <div id="sec-23" class="subsection">
                     <h3>Hypercholesterolemia</h3>
                     <p id="p-35">Hypercholesterolemia was assessed formally by only four studies (<a id="xref-ref-2-8" class="xref-bibr" href="#ref-2">2</a>,<a id="xref-ref-3-7" class="xref-bibr" href="#ref-3">3</a>,<a id="xref-ref-13-5" class="xref-bibr" href="#ref-13">13</a>,<a id="xref-ref-15-7" class="xref-bibr" href="#ref-15">15</a>) and was not graded consistently among those studies. Analysis of the pooled data showed that longer duration of aromatase
                        inhibitor use was associated with a statistically significant increase in the odds of hypercholesterolemia compared with tamoxifen
                        (OR = 2.36, 95% CI = 2.15 to 2.60, <em>P</em> &lt; .001). This effect was most apparent when up-front aromatase inhibitor use was compared with tamoxifen alone (OR = 3.14,
                        95% CI = 2.78 to 3.55, <em>P</em> &lt; .001) (<a id="xref-ref-3-8" class="xref-bibr" href="#ref-3">3</a>), less marked when up-front aromatase inhibitor use was compared with switching from tamoxifen to aromatase inhibitors (OR
                        = 1.71, 95% CI = 1.38 to 2.13, <em>P</em> &lt; .001) (<a id="xref-ref-15-8" class="xref-bibr" href="#ref-15">15</a>), and least evident when switching from tamoxifen to aromatase inhibitors was compared with tamoxifen alone (OR = 1.27, 95%
                        CI = 1.01 to 1.59, <em>P</em> = .04) (<a id="xref-ref-2-9" class="xref-bibr" href="#ref-2">2</a>,<a id="xref-ref-13-6" class="xref-bibr" href="#ref-13">13</a>). The test of subgroup differences for up-front aromatase inhibitor use vs switching from tamoxifen to aromatase inhibitors
                        was statistically significant (<em>P</em> &lt; .001), suggesting that shorter durations of aromatase inhibitors might reduce the odds of hypercholesterolemia.
                     </p>
                  </div>
                  <div id="sec-24" class="subsection">
                     <h3>Death Without Recurrence</h3>
                     <p id="p-36">In a pooled analysis, use of up-front aromatase inhibitors was associated with a non-statistically significant higher odds
                        of death without recurrence compared with use of tamoxifen alone or switching from tamoxifen to aromatase inhibitors (OR =
                        1.11, 95% CI = 0.98 to 1.26, <em>P</em> = .09). Conversely, switching from tamoxifen to aromatase inhibitors was associated with decreased odds of death without
                        recurrence compared with up-front tamoxifen for 5 years (OR = 0.75, 95% CI = 0.58 to 0.98, <em>P</em> = .04) (<a id="xref-fig-3-1" class="xref-fig" href="#F3">Figure 3</a>). The test of subgroup differences for up-front aromatase inhibitor use vs switching from tamoxifen to aromatase inhibitors
                        was statistically significant (<em>P</em> = .03), which suggests that switching to aromatase inhibitors after 2–3 years of tamoxifen may reduce the odds of death without
                        recurrent breast cancer compared with the use of either tamoxifen or aromatase inhibitors alone. Analysis of all data combined
                        revealed no association between longer duration of aromatase inhibitor use and the odds of death without recurrence (OR =
                        1.04, 95% CI = 0.93 to 1.16, <em>P</em> = .51) (<a id="xref-fig-3-2" class="xref-fig" href="#F3">Figure 3</a>). Compared with those treated with 5 years of either tamoxifen or aromatase inhibitors, those treated with a switching strategy
                        had statistically significant reduction in the odds of death without breast cancer recurrence (OR = 0.87, 95% CI = 0.77 to
                        0.99, <em>P</em> = .03). Adjustment for differential survival between the aromatase inhibitor group and the tamoxifen group did not change
                        the pooled odds ratio. In absolute terms, 4.2% of patients who received longer durations of aromatase inhibitor died without
                        breast cancer recurrence compared with 4.1% of patients treated predominantly with tamoxifen (difference in absolute risk
                        = 0.2%, number needed to harm = 610) (<a id="xref-table-wrap-2-8" class="xref-table" href="#T2">Table 2</a> and <a href="http://jnci.oxfordjournals.org/cgi/content/full/djr242/dc1">Supplementary Table 1</a>, available online).
                     </p>
                     <div id="F3" class="fig pos-float odd">
                        <div class="fig-inline"><a href="1299/F3.expansion.html"><img alt="Figure 3" src="1299/F3.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                                 <li><a href="1299/F3.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="1299/F3.expansion.html">In a new window</a></li>
                              </ul>
                              <ul class="fig-services">
                                 <li class="ppt-link"><a href="/powerpoint/103/17/1299/F3">Download as PowerPoint Slide</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="fig-caption"><span class="fig-label">Figure 3</span> 
                           <p id="p-37" class="first-child">Forest plot of odds ratios for death without breast cancer recurrence. Odds ratios for each trial are represented by the <strong>squares</strong>, the <strong>size of the square</strong> represents the weight of the trial in the meta-analysis, and the <strong>horizontal line</strong> crossing the square represents the 95% confidence interval. The <strong>diamonds</strong> represent the estimated pooled effect based for each cohort individually (labeled subtotal) and for all cohorts together
                              (labeled total). Test of subgroup differences relates to the test of heterogeneity between the three treatment cohorts as
                              defined by Deeks et al. (<a id="xref-ref-12-3" class="xref-bibr" href="#ref-12">12</a>). All <em>P</em> values are two-sided. ATAC = Anastrozole, Tamoxifen alone or in combination (<a id="xref-ref-5-8" class="xref-bibr" href="#ref-5">5</a>); BIG 1-98 = Breast International Group 01-98 (<a id="xref-ref-3-9" class="xref-bibr" href="#ref-3">3</a>); ABCSG8 = Austrian Breast Cancer Study Group VIII (<a id="xref-ref-4-9" class="xref-bibr" href="#ref-4">4</a>); ARNO = German Adjuvant Breast Cancer Group/Arimidex–Nolvadex (<a id="xref-ref-4-10" class="xref-bibr" href="#ref-4">4</a>); ITA = Italian Tamoxifen Anastrozole Trial (<a id="xref-ref-2-10" class="xref-bibr" href="#ref-2">2</a>); N-SAS BC04 = National Surgical Adjuvant Study Breast Cancer 03 trial (<a id="xref-ref-14-7" class="xref-bibr" href="#ref-14">14</a>); TEAM = Tamoxifen Exemestane Adjuvant Multinational Trial (<a id="xref-ref-15-9" class="xref-bibr" href="#ref-15">15</a>); AI = aromatase inhibitor; CI = confidence interval; OR = odds ratio.
                           </p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                  </div>
               </div>
               <div class="section discussion" id="sec-25">
                  <div class="section-nav"><a href="#sec-16" title="Results" class="prev-section-link"><span>Previous Section</span></a><a href="#fn-group-1" title="Footnotes" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Discussion</h2>
                  <p id="p-38">This systematic review and meta-analysis shows that, compared with tamoxifen, the use of aromatase inhibitors in postmenopausal
                     women with early-stage breast cancer increases the odds of developing cardiovascular disease and bone fractures and decreases
                     the odds of venous thrombosis and endometrial carcinoma. There were no differences in the odds of cerebrovascular disease,
                     other second cancers, or death without breast cancer recurrence between treatment strategies.
                  </p>
                  <p id="p-39">Aromatase inhibitors can reduce recurrence of breast cancer, and pooled trial data show that they improve disease-free survival
                     (<a id="xref-ref-6-4" class="xref-bibr" href="#ref-6">6</a>). However, in most trials, the improvement in breast cancer–specific outcomes has not resulted in subsequent improvement
                     in overall survival. The lack of association between disease-free survival and overall survival requires careful evaluation
                     of the toxicities of different endocrine therapy options. Tamoxifen and aromatase inhibitors have distinct toxicity profiles;
                     however, individual trials have not shown a statistically significant difference in overall toxicity between patients treated
                     with these therapies. Although randomized trials may have enough statistical power to detect differences in common toxicities
                     between treatment groups, they typically lack statistical power to detect differences in rare but potentially serious adverse
                     events (<a id="xref-ref-16-1" class="xref-bibr" href="#ref-16">16</a>). A previous attempt (<a id="xref-ref-17-1" class="xref-bibr" href="#ref-17">17</a>) to pool trial data to assess the differential toxicity of aromatase inhibitors and tamoxifen was based on a limited number
                     of studies with relatively short follow-up. These limitations have been addressed in this study.
                  </p>
                  <p id="p-40">Our data show that aromatase inhibitors and tamoxifen have different toxicity profiles (<a id="xref-fig-2-9" class="xref-fig" href="#F2">Figure 2</a> and <a id="xref-table-wrap-2-9" class="xref-table" href="#T2">Table 2</a>). Many of the included adverse events were rare; therefore, if clinical decisions are made based on these data, they should
                     be based on absolute risk (or number needed to harm) rather than relative risk, which can be confusing especially for endpoints
                     of varying frequencies. Furthermore, because individual patients may have experienced more than one adverse event, absolute
                     risks for the different adverse events should not be summed as this is not equivalent to the number of patients with one or
                     more adverse event. For cardiovascular events, pooled data showed that longer durations of aromatase inhibitor use are associated
                     with a statistically significantly higher odds of developing such events compared with tamoxifen alone or a shorter period
                     of aromatase inhibitor use after an initial period of tamoxifen therapy (OR = 1.26, <em>P</em> &lt; .001). The effect size demonstrated in individual trials was consistent among all included studies, and this finding was
                     independent of whether patients received up-front aromatase inhibitors or whether aromatase inhibitors were given after 2–3
                     years of tamoxifen. Although the effect sizes corresponded to only a small increase in the absolute risk of cardiovascular
                     disease in the overall population of women who received adjuvant hormonal therapy (&lt;1%, number needed to harm = 132), it is
                     possible that specific subpopulations of patients are at higher risk. For example, the US Food and Drug Administration–revised
                     label for anastrozole (<a id="xref-ref-18-1" class="xref-bibr" href="#ref-18">18</a>) states that in women with preexisting heart disease in the ATAC trial (7.5% of the total trial population) (<a id="xref-ref-5-9" class="xref-bibr" href="#ref-5">5</a>), the incidence of cardiovascular events was 17% with anastrozole and 10% with tamoxifen and urges physicians to consider
                     the risks and benefits of anastrozole therapy in such patients. To our knowledge, this important information has not been
                     published in the scientific literature. Our data suggest that the increased risk of cardiovascular events in women with preexisting
                     heart disease is not confined to anastrozole, but may be a class effect for aromatase inhibitors.
                  </p>
                  <p id="p-41">There are several possible explanations for the finding of an increased number of cardiovascular events with aromatase inhibitors
                     compared with tamoxifen. First, data from male mice show that aromatase inhibitors may have a direct effect on endothelium
                     that may predispose the mice to the development of atherosclerosis (<a id="xref-ref-19-1" class="xref-bibr" href="#ref-19">19</a>). Second, hypercholesterolemia is a well-known risk factor for the development of cardiovascular disease. Our pooled analysis
                     showed that aromatase inhibitor use was associated with a statistically significantly increased odds of hypercholesterolemia
                     compared with tamoxifen use (OR = 2.36, <em>P</em> &lt; .001). This effect was most apparent with longer durations of aromatase inhibitor use, suggesting that it is the cumulative
                     exposure to aromatase inhibitors that is important. However, we cannot exclude the possible effect of interstudy differences
                     in duration of follow-up, given that vascular events are likely to accumulate for an extended period after a rise in cholesterol.
                     Increases in hypercholesterolemia and serious cardiovascular events with aromatase inhibitors compared with tamoxifen were
                     also demonstrated in a combined analysis of the up-front and sequencing arms of the BIG 1-98 study (<a id="xref-ref-20-1" class="xref-bibr" href="#ref-20">20</a>). Finally, randomized and observational comparisons of tamoxifen vs placebo or no treatment have shown that tamoxifen is
                     associated with a reduction in cardiovascular events (<a id="xref-ref-21-1" class="xref-bibr" href="#ref-21">21</a>–<a id="xref-ref-24-1" class="xref-bibr" href="#ref-24">24</a>). Therefore, any comparison with tamoxifen may be confounded. Unfortunately, data on the independent effect of aromatase
                     inhibitors on cardiovascular events is unreliable as reporting of such events in women participating in trials of aromatase
                     inhibitors or placebo is variable. For example, data from the National Cancer Institute of Canada MA.17 trial of letrozole
                     vs placebo after an initial 5 years of tamoxifen showed little difference in cardiovascular events between the study arms
                     (<a id="xref-ref-25-1" class="xref-bibr" href="#ref-25">25</a>). Moreover, cardiovascular adverse events were not reported at all in two other randomized trials also conducted in the extended
                     adjuvant setting (<a id="xref-ref-26-1" class="xref-bibr" href="#ref-26">26</a>,<a id="xref-ref-27-1" class="xref-bibr" href="#ref-27">27</a>). The prolonged protective effect of tamoxifen in patients receiving aromatase inhibitors after 5 years of initial tamoxifen
                     therapy cannot be excluded (<a id="xref-ref-28-1" class="xref-bibr" href="#ref-28">28</a>).
                  </p>
                  <p id="p-42">Oncologists should therefore consider carefully the risks and benefits of aromatase inhibitors in patients with preexisting
                     heart disease or related risk factors. This is especially important in the extended adjuvant setting, where predictive factors
                     for benefit remain scarce, and the potential harm from ongoing aromatase inhibitor therapy may outweigh any small reductions
                     in the recurrence of breast cancer.
                  </p>
                  <p id="p-43">We found no statistically significant difference between aromatase inhibitors and tamoxifen in the odds of cerebrovascular
                     disease. However, we cannot exclude the possibility that differences in the risk of cerebrovascular disease may become more
                     apparent with longer follow-up of trial participants. The overlapping risk factors for the development of cardiovascular and
                     cerebrovascular disease, including hypercholesterolemia, which is increased by aromatase inhibitors, might ultimately lead
                     to an increase risk of cerebrovascular disease as well as of cardiovascular disease with aromatase inhibitors. Conversely,
                     susceptibility to thrombosis is a recognized risk factor for cerebrovascular disease (<a id="xref-ref-29-1" class="xref-bibr" href="#ref-29">29</a>,<a id="xref-ref-30-1" class="xref-bibr" href="#ref-30">30</a>). The procoagulant effects of tamoxifen may offset any increase in risk of cerebrovascular events resulting from hypercholesterolemia
                     with aromatase inhibitors.
                  </p>
                  <p id="p-44">Our data suggest that up-front use of aromatase inhibitors is associated with increased odds of death without breast cancer
                     recurrence compared with the use of tamoxifen alone or a switch to aromatase inhibitors after 2–3 years of tamoxifen. This
                     finding may explain why up-front use of aromatase inhibitors improves disease-free survival but not overall survival. Furthermore,
                     our data suggest that switching to aromatase inhibitors after 2–3 years of tamoxifen is associated with a reduction in the
                     number of deaths without breast cancer recurrence compared with the use of either tamoxifen or aromatase inhibitors alone.
                     One explanation for this finding is a reduction in risk of cumulative toxicities brought about by switching from one agent
                     to another. These hypothesis-generating data appear to support the use of switching strategies as a way to reduce cumulative
                     toxicities and may be particularly relevant among older women. For example, a secondary analysis of the ATAC trial showed
                     that older age and increasing number of comorbidities were associated with a substantially increased risk of death without
                     recurrence in women with lymph node–negative breast cancer (<a id="xref-ref-31-1" class="xref-bibr" href="#ref-31">31</a>).
                  </p>
                  <p id="p-45">From a clinical viewpoint, our data on cardiovascular adverse events suggest that the use of aromatase inhibitors for postmenopausal
                     women with ischemic heart disease should be considered on an individual basis. In patients who are at a lower risk of breast
                     cancer recurrence and for whom the absolute benefits of aromatase inhibitors are reduced, use of these agents should be avoided.
                     In those who are at higher risk of breast cancer recurrence, the absolute benefit of aromatase inhibitors is greater and therefore
                     these agents should be used in sequence with tamoxifen. Conversely, patients with a personal or family history of thromboembolic
                     disease should probably avoid tamoxifen (<a id="xref-ref-32-1" class="xref-bibr" href="#ref-32">32</a>). These data may help physicians to better counsel patients with risk factors for toxicities from both treatments about their
                     treatment options.
                  </p>
                  <p id="p-46">Our pooled data are consistent with data reported previously in the individual studies, which showed that compared with tamoxifen,
                     aromatase inhibitors are associated with increased odds of bone fracture (OR = 1.47, <em>P</em> &lt; .001) and reduced odds of venous thrombosis (OR = 0.52, <em>P</em> &lt; .001) and endometrial carcinoma (OR = 0.34, <em>P</em> &lt; .001). Switching from one agent to another did not appear to modify the relative risks of developing these adverse events.
                     However, in most of the switching studies included in this meta-analysis, randomization to an aromatase inhibitor occurred
                     after an initial 2–3 years of tamoxifen, and toxicities that occurred before randomization were not recorded. Furthermore,
                     because our analysis was based on intention to treat, any patients who crossed over from the tamoxifen arms to aromatase inhibitors
                     may have reduced protection from toxicity associated with switching strategies.
                  </p>
                  <p id="p-47">This study has several limitations. First, this is a meta-analysis of the literature rather than of individual patient data
                     and is based on reports of trials with different durations of follow-up; we were not able to report actuarial rates of toxicity.
                     Second, collection of data for the purpose of this meta-analysis was dependent on the rigorous collection and reporting of
                     adverse events by the investigators, and the quality of such reporting is known to be variable (<a id="xref-ref-33-1" class="xref-bibr" href="#ref-33">33</a>). Furthermore, adverse events are usually collected in intervention trials only until an event of interest occurs, such as
                     breast cancer recurrence (the primary endpoint in these trials). However, adverse events after breast cancer recurrence remain
                     of interest because most women with hormone receptor–positive breast cancer survive for several years, even with metastatic
                     disease. Such data were not available for the trials included in this meta-analysis. Third, information on the potentially
                     confounding baseline host factors (eg, obesity, hypertension, diabetes, and family history of events of interest) or the use
                     of concurrent medications was not available and therefore their effects on the odds of the adverse events could not be quantified.
                     Finally, our analysis included all grades of toxicity. Higher-grade toxicities have more profound early implications; however,
                     the influence of grading of toxicity on long-term health outcomes is unclear. In keeping with our objective to explore serious
                     and/or potentially life-threatening toxicities, we felt that inclusion of all grades of toxicity was important.
                  </p>
                  <p id="p-48">Despite these limitations, this study demonstrates a statistically significant and consistent increase in cardiovascular risk
                     associated with the use of aromatase inhibitors. Although the increase in absolute risk is small in the general population,
                     it is likely to be higher in patients with preexisting cardiovascular disease or risk factors associated with it. Given our
                     finding, that aromatase inhibitor use is associated with a greater than twofold increase in the odds of hypercholesterolemia,
                     the risk of cardiovascular events may increase further with longer follow-up of patients on these trials. Furthermore, our
                     data suggest an increase in the risk of death without breast cancer recurrence associated with the use of either tamoxifen
                     or aromatase inhibitors alone compared with the use of aromatase inhibitors after 2–3 years of tamoxifen. Switching from tamoxifen
                     to aromatase inhibitors appears to be the optimal strategy for offsetting serious adverse events of individual drugs.
                  </p>
                  <p id="p-49">In conclusion, we urge clinicians to consider carefully the toxicity profiles of different endocrine therapy options for breast
                     cancer and choose those that best suit their patients’ baseline health characteristics. Investigators participating in practice-changing
                     clinical trials or in trial overviews should rigorously report not only efficacy data but also data on less common and potentially
                     serious toxicities.
                  </p>
                  <div id="sec-26" class="subsection">
                     <h3>Funding</h3>
                     <p id="p-50">Asociación Española Contra el Cáncer and Fondo de Investigaciones Sanitarias (PI09/2144 to A.O.).</p>
                  </div>
               </div>
               <div class="section fn-group" id="fn-group-1">
                  <div class="section-nav"><a href="#sec-25" title="Discussion" class="prev-section-link"><span>Previous Section</span></a><a href="#ref-list-1" title="References" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Footnotes</h2>
                  <ul>
                     <li class="fn" id="fn-6">
                        <p id="p-51">The authors would like to acknowledge the input of Dr Ian Tannock and Dr Philippe Bedard in earlier versions of this article.
                           The study sponsors did not have any role in the design of the study; the collection, analysis, or interpretation of the data;
                           the writing of the article; or the decision to submit the article for publication.
                        </p>
                     </li>
                  </ul>
               </div>
               <ul class="copyright-statement">
                  <li class="fn" id="copyright-statement-1">© The Author 2011. Published by Oxford University Press.</li>
               </ul>
               <div class="section ref-list" id="ref-list-1">
                  <div class="section-nav"><a href="#fn-group-1" title="Footnotes" class="prev-section-link"><span>Previous Section</span></a><div class="nav-placeholder"> </div>
                  </div>
                  <h2>References</h2>
                  <ol class="cit-list ref-use-labels">
                     <li><span class="ref-label">1.</span><a class="rev-xref-ref" href="#xref-ref-1-1" title="View reference 1. in text"
                           id="ref-1">↵</a><div class="cit ref-cit ref-journal" id="cit-103.17.1299.1"
                             data-doi="10.1056/NEJMra023246">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Smith</span>  <span class="cit-name-given-names">IE</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Dowsett</span>  <span class="cit-name-given-names">M</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Aromatase inhibitors in breast cancer</span>. <abbr class="cit-jnl-abbrev">N Engl J Med.</abbr> <span class="cit-pub-date">2003</span>;<span class="cit-vol">348</span>(<span class="cit-issue">24</span>):<span class="cit-fpage">2431</span>-<span class="cit-lpage">2442</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJMra023246&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12802030&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000183428900010&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Aromatase%20inhibitors%20in%20breast%20cancer&amp;author=IE%20Smith&amp;author=M%20Dowsett&amp;publication_year=2003&amp;journal=N%20Engl%20J%20Med.&amp;volume=348&amp;issue=24&amp;pages=2431-2442">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">2.</span><a class="rev-xref-ref" href="#xref-ref-2-1" title="View reference 2. in text"
                           id="ref-2">↵</a><div class="cit ref-cit ref-journal" id="cit-103.17.1299.2"
                             data-doi="10.1093/annonc/mdl941">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Boccardo</span>  <span class="cit-name-given-names">F</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Rubagotti</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Guglielmini</span>  <span class="cit-name-given-names">P</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen
                                    anastrozole (ITA) trial</span>. <abbr class="cit-jnl-abbrev">Ann Oncol.</abbr> <span class="cit-pub-date">2006</span>;<span class="cit-vol">17</span> <span class="cit-supplement">suppl 7</span>:<span class="cit-fpage">vii10</span>-<span class="cit-lpage">vii14</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=annonc&amp;resid=17/suppl_7/vii10"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">3.</span><a class="rev-xref-ref" href="#xref-ref-3-1" title="View reference 3. in text"
                           id="ref-3">↵</a><div class="cit ref-cit ref-journal" id="cit-103.17.1299.3"
                             data-doi="10.1200/JCO.2006.08.8617">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Coates</span>  <span class="cit-name-given-names">AS</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Keshaviah</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Thurlimann</span>  <span class="cit-name-given-names">B</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive
                                    early breast cancer: update of study BIG 1-98</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol.</abbr> <span class="cit-pub-date">2007</span>;<span class="cit-vol">25</span>(<span class="cit-issue">5</span>):<span class="cit-fpage">486</span>-<span class="cit-lpage">492</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=25/5/486"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">4.</span><a class="rev-xref-ref" href="#xref-ref-4-1" title="View reference 4. in text"
                           id="ref-4">↵</a><div class="cit ref-cit ref-journal" id="cit-103.17.1299.4"
                             data-doi="10.1016/S0140-6736(05)67059-6">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Jakesz</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Jonat</span>  <span class="cit-name-given-names">W</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Gnant</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen:
                                    combined results of ABCSG trial 8 and ARNO 95 trial</span>. <abbr class="cit-jnl-abbrev">Lancet.</abbr> <span class="cit-pub-date">2005</span>;<span class="cit-vol">366</span>(<span class="cit-issue">9484</span>):<span class="cit-fpage">455</span>-<span class="cit-lpage">462</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0140-6736(05)67059-6&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=16084253&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000231022300026&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Switching%20of%20postmenopausal%20women%20with%20endocrine-responsive%20early%20breast%20cancer%20to%20anastrozole%20after%202%20years%E2%80%99%20adjuvant%20tamoxifen%3A%20combined%20results%20of%20ABCSG%20trial%208%20and%20ARNO%2095%20trial&amp;author=R%20Jakesz&amp;author=W%20Jonat&amp;author=M%20Gnant&amp;publication_year=2005&amp;journal=Lancet.&amp;volume=366&amp;issue=9484&amp;pages=455-462">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">5.</span><a class="rev-xref-ref" href="#xref-ref-5-1" title="View reference 5. in text"
                           id="ref-5">↵</a><div class="cit ref-cit ref-journal" id="cit-103.17.1299.5"
                             data-doi="10.1016/S1470-2045(07)70385-6">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Forbes</span>  <span class="cit-name-given-names">JF</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Cuzick</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Buzdar</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Howell</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Tobias</span>  <span class="cit-name-given-names">JS</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Baum</span>  <span class="cit-name-given-names">M</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial</span>. <abbr class="cit-jnl-abbrev">Lancet Oncol.</abbr> <span class="cit-pub-date">2008</span>;<span class="cit-vol">9</span>(<span class="cit-issue">1</span>):<span class="cit-fpage">45</span>-<span class="cit-lpage">53</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S1470-2045(07)70385-6&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=18083636&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000252464400025&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Effect%20of%20anastrozole%20and%20tamoxifen%20as%20adjuvant%20treatment%20for%20early-stage%20breast%20cancer%3A%20100-month%20analysis%20of%20the%20ATAC%20trial&amp;author=JF%20Forbes&amp;author=J%20Cuzick&amp;author=A%20Buzdar&amp;author=A%20Howell&amp;author=JS%20Tobias&amp;author=M%20Baum&amp;publication_year=2008&amp;journal=Lancet%20Oncol.&amp;volume=9&amp;issue=1&amp;pages=45-53">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">6.</span><a class="rev-xref-ref" href="#xref-ref-6-1" title="View reference 6. in text"
                           id="ref-6">↵</a><div class="cit ref-cit ref-journal" id="cit-103.17.1299.6"
                             data-doi="10.1200/JCO.2009.23.1274">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Dowsett</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Cuzick</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ingle</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol.</abbr> <span class="cit-pub-date">2010</span>;<span class="cit-vol">28</span>(<span class="cit-issue">3</span>):<span class="cit-fpage">509</span>-<span class="cit-lpage">518</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=28/3/509"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">7.</span><a class="rev-xref-ref" href="#xref-ref-7-1" title="View reference 7. in text"
                           id="ref-7">↵</a><div class="cit ref-cit ref-journal" id="cit-103.17.1299.7"
                             data-doi="10.1200/JCO.2008.19.5594">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Seruga</span>  <span class="cit-name-given-names">B</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Tannock</span>  <span class="cit-name-given-names">IF</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol.</abbr> <span class="cit-pub-date">2009</span>;<span class="cit-vol">27</span>(<span class="cit-issue">6</span>):<span class="cit-fpage">840</span>-<span class="cit-lpage">842</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=FULL&amp;journalCode=jco&amp;resid=27/6/840"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">8.</span><a class="rev-xref-ref" href="#xref-ref-8-1" title="View reference 8. in text"
                           id="ref-8">↵</a><div class="cit ref-cit ref-journal" id="cit-103.17.1299.8"
                             data-doi="10.1038/sj.bjc.6605231">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Hughes-Davies</span>  <span class="cit-name-given-names">L</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Caldas</span>  <span class="cit-name-given-names">C</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Wishart</span>  <span class="cit-name-given-names">GC</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Tamoxifen: the drug that came in from the cold</span>. <abbr class="cit-jnl-abbrev">Br J Cancer.</abbr> <span class="cit-pub-date">2009</span>;<span class="cit-vol">101</span>(<span class="cit-issue">6</span>):<span class="cit-fpage">875</span>-<span class="cit-lpage">878</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1038/sj.bjc.6605231&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=19672259&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000269617200001&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Tamoxifen%3A%20the%20drug%20that%20came%20in%20from%20the%20cold&amp;author=L%20Hughes-Davies&amp;author=C%20Caldas&amp;author=GC%20Wishart&amp;publication_year=2009&amp;journal=Br%20J%20Cancer.&amp;volume=101&amp;issue=6&amp;pages=875-878">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">9.</span><a class="rev-xref-ref" href="#xref-ref-9-1" title="View reference 9. in text"
                           id="ref-9">↵</a><div class="cit ref-cit ref-journal" id="cit-103.17.1299.9"
                             data-doi="10.1200/JCO.2010.28.3564">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Seruga</span>  <span class="cit-name-given-names">B</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ocana</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Niraula</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Amir</span>  <span class="cit-name-given-names">E</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Absolute benefits of aromatase inhibitors in adjuvant treatment of breast cancer: should we know more?</span> <abbr class="cit-jnl-abbrev">J Clin Oncol.</abbr> <span class="cit-pub-date">2010</span>;<span class="cit-vol">28</span>(<span class="cit-issue">20</span>):<span class="cit-fpage">e346</span>-<span class="cit-lpage">347</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=FULL&amp;journalCode=jco&amp;resid=28/20/e346"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">10.</span><a class="rev-xref-ref" href="#xref-ref-10-1" title="View reference 10. in text"
                           id="ref-10">↵</a><div class="cit ref-cit ref-journal" id="cit-103.17.1299.10"
                             data-doi="10.1016/0197-2456(86)90046-2">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">DerSimonian</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Laird</span>  <span class="cit-name-given-names">N</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Meta-analysis in clinical trials</span>. <abbr class="cit-jnl-abbrev">Control Clin Trials.</abbr> <span class="cit-pub-date">1986</span>;<span class="cit-vol">7</span>(<span class="cit-issue">3</span>):<span class="cit-fpage">177</span>-<span class="cit-lpage">188</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/0197-2456(86)90046-2&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=3802833&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1986F013900001&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Meta-analysis%20in%20clinical%20trials&amp;author=R%20DerSimonian&amp;author=N%20Laird&amp;publication_year=1986&amp;journal=Control%20Clin%20Trials.&amp;volume=7&amp;issue=3&amp;pages=177-188">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">11.</span><a class="rev-xref-ref" href="#xref-ref-11-1" title="View reference 11. in text"
                           id="ref-11">↵</a><div class="cit ref-cit ref-book" id="cit-103.17.1299.11">
                           <div class="cit-metadata">
                              <ol class="cit-ed-list">
                                 <li><span class="cit-ed"><span class="cit-name-surname">Deeks</span>  <span class="cit-name-given-names">JJ</span></span>, 
                                 </li>
                                 <li><span class="cit-ed"><span class="cit-name-surname">Higgins</span>  <span class="cit-name-given-names">JPT</span></span>, 
                                 </li>
                                 <li><span class="cit-ed"><span class="cit-name-surname">Altman</span>  <span class="cit-name-given-names">DG</span></span></li>
                              </ol><cite>, editors. <span class="cit-source">Analysing and presenting results. Cochrane Handbook for Systematic Reviews of Interventions 4 2 5</span>. <span class="cit-comment">In: The Cochrane Library; Chichester, UK: John Wiley &amp; Sons, Ltd; 2006</span>.</cite></div>
                           <div class="cit-extra"><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Analysing%20and%20presenting%20results.%20Cochrane%20Handbook%20for%20Systematic%20Reviews%20of%20Interventions%204%202%205&amp;author=JJ%20Deeks&amp;author=JPT%20Higgins&amp;author=DG%20Altman">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">12.</span><a class="rev-xref-ref" href="#xref-ref-12-1" title="View reference 12. in text"
                           id="ref-12">↵</a><div class="cit ref-cit ref-journal" id="cit-103.17.1299.12"
                             data-doi="10.1136/bmj.323.7305.157">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Deeks</span>  <span class="cit-name-given-names">JJ</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests</span>. <abbr class="cit-jnl-abbrev">BMJ.</abbr> <span class="cit-pub-date">2001</span>;<span class="cit-vol">323</span>(<span class="cit-issue">7305</span>):<span class="cit-fpage">157</span>-<span class="cit-lpage">162</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=FULL&amp;journalCode=bmj&amp;resid=323/7305/157"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">13.</span><a class="rev-xref-ref" href="#xref-ref-13-1" title="View reference 13. in text"
                           id="ref-13">↵</a><div class="cit ref-cit ref-journal" id="cit-103.17.1299.13"
                             data-doi="10.1016/S0140-6736(07)60200-1">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Coombes</span>  <span class="cit-name-given-names">RC</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Kilburn</span>  <span class="cit-name-given-names">LS</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Snowdon</span>  <span class="cit-name-given-names">CF</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised
                                    controlled trial</span>. <abbr class="cit-jnl-abbrev">Lancet.</abbr> <span class="cit-pub-date">2007</span>;<span class="cit-vol">369</span>(<span class="cit-issue">9561</span>):<span class="cit-fpage">559</span>-<span class="cit-lpage">570</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0140-6736(07)60200-1&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=17307102&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000244368000029&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Survival%20and%20safety%20of%20exemestane%20versus%20tamoxifen%20after%202%E2%80%933%20years%E2%80%99%20tamoxifen%20treatment%20%28Intergroup%20Exemestane%20Study%29%3A%20a%20randomised%20controlled%20trial&amp;author=RC%20Coombes&amp;author=LS%20Kilburn&amp;author=CF%20Snowdon&amp;publication_year=2007&amp;journal=Lancet.&amp;volume=369&amp;issue=9561&amp;pages=559-570">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">14.</span><a class="rev-xref-ref" href="#xref-ref-14-1" title="View reference 14. in text"
                           id="ref-14">↵</a><div class="cit ref-cit ref-journal" id="cit-103.17.1299.14"
                             data-doi="10.1007/s10549-010-0888-x">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Aihara</span>  <span class="cit-name-given-names">T</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Takatsuka</span>  <span class="cit-name-given-names">Y</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ohsumi</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal
                                    women with hormone-responsive breast cancer: N-SAS BC03 study</span>. <abbr class="cit-jnl-abbrev">Breast Cancer Res Treat.</abbr> <span class="cit-pub-date">2010</span>;<span class="cit-vol">121</span>(<span class="cit-issue">2</span>):<span class="cit-fpage">379</span>-<span class="cit-lpage">387</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1007/s10549-010-0888-x&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=20390343&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000277906500013&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Phase%20III%20randomized%20adjuvant%20study%20of%20tamoxifen%20alone%20versus%20sequential%20tamoxifen%20and%20anastrozole%20in%20Japanese%20postmenopausal%20women%20with%20hormone-responsive%20breast%20cancer%3A%20N-SAS%20BC03%20study&amp;author=T%20Aihara&amp;author=Y%20Takatsuka&amp;author=S%20Ohsumi&amp;publication_year=2010&amp;journal=Breast%20Cancer%20Res%20Treat.&amp;volume=121&amp;issue=2&amp;pages=379-387">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">15.</span><a class="rev-xref-ref" href="#xref-ref-15-1" title="View reference 15. in text"
                           id="ref-15">↵</a><div class="cit ref-cit ref-journal" id="cit-103.17.1299.15"
                             data-doi="10.1016/S0140-6736(10)62312-4">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">van de Velde</span>  <span class="cit-name-given-names">CJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Rea</span>  <span class="cit-name-given-names">D</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Seynaeve</span>  <span class="cit-name-given-names">C</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial</span>. <abbr class="cit-jnl-abbrev">Lancet.</abbr> <span class="cit-pub-date">2011</span>;<span class="cit-vol">377</span>(<span class="cit-issue">9762</span>):<span class="cit-fpage">321</span>-<span class="cit-lpage">331</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0140-6736(10)62312-4&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=21247627&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000286850400029&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Adjuvant%20tamoxifen%20and%20exemestane%20in%20early%20breast%20cancer%20%28TEAM%29%3A%20a%20randomised%20phase%203%20trial&amp;author=CJ%20van%20de%20Velde&amp;author=D%20Rea&amp;author=C%20Seynaeve&amp;publication_year=2011&amp;journal=Lancet.&amp;volume=377&amp;issue=9762&amp;pages=321-331">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">16.</span><a class="rev-xref-ref" href="#xref-ref-16-1" title="View reference 16. in text"
                           id="ref-16">↵</a><div class="cit ref-cit ref-journal" id="cit-103.17.1299.16"
                             data-doi="10.1016/j.jclinepi.2008.08.005">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Tsang</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Colley</span>  <span class="cit-name-given-names">L</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Lynd</span>  <span class="cit-name-given-names">LD</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Inadequate statistical power to detect clinically significant differences in adverse event rates in randomized controlled
                                    trials</span>. <abbr class="cit-jnl-abbrev">J Clin Epidemiol.</abbr> <span class="cit-pub-date">2009</span>;<span class="cit-vol">62</span>(<span class="cit-issue">6</span>):<span class="cit-fpage">609</span>-<span class="cit-lpage">616</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/j.jclinepi.2008.08.005&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=19013761&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000266291600010&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Inadequate%20statistical%20power%20to%20detect%20clinically%20significant%20differences%20in%20adverse%20event%20rates%20in%20randomized%20controlled%20trials&amp;author=R%20Tsang&amp;author=L%20Colley&amp;author=LD%20Lynd&amp;publication_year=2009&amp;journal=J%20Clin%20Epidemiol.&amp;volume=62&amp;issue=6&amp;pages=609-616">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">17.</span><a class="rev-xref-ref" href="#xref-ref-17-1" title="View reference 17. in text"
                           id="ref-17">↵</a><div class="cit ref-cit ref-journal" id="cit-103.17.1299.17"
                             data-doi="10.1002/cncr.23171">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Cuppone</span>  <span class="cit-name-given-names">F</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bria</span>  <span class="cit-name-given-names">E</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Verma</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis
                                    of randomized trials</span>. <abbr class="cit-jnl-abbrev">Cancer.</abbr> <span class="cit-pub-date">2008</span>;<span class="cit-vol">112</span>(<span class="cit-issue">2</span>):<span class="cit-fpage">260</span>-<span class="cit-lpage">267</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/cncr.23171&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=18041059&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000252266200005&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Do%20adjuvant%20aromatase%20inhibitors%20increase%20the%20cardiovascular%20risk%20in%20postmenopausal%20women%20with%20early%20breast%20cancer%3F%20Meta-analysis%20of%20randomized%20trials&amp;author=F%20Cuppone&amp;author=E%20Bria&amp;author=S%20Verma&amp;publication_year=2008&amp;journal=Cancer.&amp;volume=112&amp;issue=2&amp;pages=260-267">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">18.</span><a class="rev-xref-ref" href="#xref-ref-18-1" title="View reference 18. in text"
                           id="ref-18">↵</a><div class="cit ref-cit ref-book" id="cit-103.17.1299.18">
                           <div class="cit-metadata"><cite><span class="cit-auth cit-collab">Food and Drug Administration</span>. <span class="cit-source">Anastrozole: Full Prescribing Information</span>. <span class="cit-comment"><a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020541s024s025lbl.pdf">http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020541s024s025lbl.pdf</a>. Accessed November 11, 2010</span>.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                     </li>
                     <li><span class="ref-label">19.</span><a class="rev-xref-ref" href="#xref-ref-19-1" title="View reference 19. in text"
                           id="ref-19">↵</a><div class="cit ref-cit ref-journal" id="cit-103.17.1299.19"
                             data-doi="10.1073/pnas.051003698">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Nathan</span>  <span class="cit-name-given-names">L</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Shi</span>  <span class="cit-name-given-names">W</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Dinh</span>  <span class="cit-name-given-names">H</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Testosterone inhibits early atherogenesis by conversion to estradiol: critical role of aromatase</span>. <abbr class="cit-jnl-abbrev">Proc Natl Acad Sci U S A.</abbr> <span class="cit-pub-date">2001</span>;<span class="cit-vol">98</span>(<span class="cit-issue">6</span>):<span class="cit-fpage">3589</span>-<span class="cit-lpage">3593</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=pnas&amp;resid=98/6/3589"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">20.</span><a class="rev-xref-ref" href="#xref-ref-20-1" title="View reference 20. in text"
                           id="ref-20">↵</a><div class="cit ref-cit ref-journal" id="cit-103.17.1299.20"
                             data-doi="10.1200/JCO.2007.12.1665">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Mouridsen</span>  <span class="cit-name-given-names">H</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Keshaviah</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Coates</span>  <span class="cit-name-given-names">AS</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety
                                    analysis of BIG 1-98 trial</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol.</abbr> <span class="cit-pub-date">2007</span>;<span class="cit-vol">25</span>(<span class="cit-issue">36</span>):<span class="cit-fpage">5715</span>-<span class="cit-lpage">5722</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=25/36/5715"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">21.</span><a class="rev-xref-ref" href="#xref-ref-21-1" title="View reference 21. in text"
                           id="ref-21">↵</a><div class="cit ref-cit ref-journal" id="cit-103.17.1299.21">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Love</span>  <span class="cit-name-given-names">RR</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Wiebe</span>  <span class="cit-name-given-names">DA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Newcomb</span>  <span class="cit-name-given-names">PA</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Effects of tamoxifen on cardiovascular risk factors in postmenopausal women</span>. <abbr class="cit-jnl-abbrev">Ann Intern Med.</abbr> <span class="cit-pub-date">1991</span>;<span class="cit-vol">115</span>(<span class="cit-issue">11</span>):<span class="cit-fpage">860</span>-<span class="cit-lpage">864</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=1952472&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1991GR17100004&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Effects%20of%20tamoxifen%20on%20cardiovascular%20risk%20factors%20in%20postmenopausal%20women&amp;author=RR%20Love&amp;author=DA%20Wiebe&amp;author=PA%20Newcomb&amp;publication_year=1991&amp;journal=Ann%20Intern%20Med.&amp;volume=115&amp;issue=11&amp;pages=860-864">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">22.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-103.17.1299.22"
                             data-doi="10.1210/jc.80.11.3191">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Grey</span>  <span class="cit-name-given-names">AB</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Stapleton</span>  <span class="cit-name-given-names">JP</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Evans</span>  <span class="cit-name-given-names">MC</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Reid</span>  <span class="cit-name-given-names">IR</span></span></li>
                              </ol><cite>. <span class="cit-article-title">The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women</span>. <abbr class="cit-jnl-abbrev">J Clin Endocrinol Metab.</abbr> <span class="cit-pub-date">1995</span>;<span class="cit-vol">80</span>(<span class="cit-issue">11</span>):<span class="cit-fpage">3191</span>-<span class="cit-lpage">3195</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1210/jc.80.11.3191&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=7593425&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1995TD90900018&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=The%20effect%20of%20the%20anti-estrogen%20tamoxifen%20on%20cardiovascular%20risk%20factors%20in%20normal%20postmenopausal%20women&amp;author=AB%20Grey&amp;author=JP%20Stapleton&amp;author=MC%20Evans&amp;author=IR%20Reid&amp;publication_year=1995&amp;journal=J%20Clin%20Endocrinol%20Metab.&amp;volume=80&amp;issue=11&amp;pages=3191-3195">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">23.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-103.17.1299.23"
                             data-doi="10.1093/jnci/85.17.1398">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Rutqvist</span>  <span class="cit-name-given-names">LE</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Mattsson</span>  <span class="cit-name-given-names">A</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant
                                    tamoxifen. The Stockholm Breast Cancer Study Group</span>. <abbr class="cit-jnl-abbrev">J Natl Cancer Inst.</abbr> <span class="cit-pub-date">1993</span>;<span class="cit-vol">85</span>(<span class="cit-issue">17</span>):<span class="cit-fpage">1398</span>-<span class="cit-lpage">1406</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jnci&amp;resid=85/17/1398"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">24.</span><a class="rev-xref-ref" href="#xref-ref-24-1" title="View reference 24. in text"
                           id="ref-24">↵</a><div class="cit ref-cit ref-journal" id="cit-103.17.1299.24">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">McDonald</span>  <span class="cit-name-given-names">CC</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Alexander</span>  <span class="cit-name-given-names">FE</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Whyte</span>  <span class="cit-name-given-names">BW</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Forrest</span>  <span class="cit-name-given-names">AP</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Stewart</span>  <span class="cit-name-given-names">HJ</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish
                                    Cancer Trials Breast Group</span>. <abbr class="cit-jnl-abbrev">BMJ.</abbr> <span class="cit-pub-date">1995</span>;<span class="cit-vol">311</span>(<span class="cit-issue">7011</span>):<span class="cit-fpage">977</span>-<span class="cit-lpage">980</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=bmj&amp;resid=311/7011/977"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">25.</span><a class="rev-xref-ref" href="#xref-ref-25-1" title="View reference 25. in text"
                           id="ref-25">↵</a><div class="cit ref-cit ref-journal" id="cit-103.17.1299.25"
                             data-doi="10.1093/jnci/dji250">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Goss</span>  <span class="cit-name-given-names">PE</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ingle</span>  <span class="cit-name-given-names">JN</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Martino</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated
                                    findings from NCIC CTG MA.17</span>. <abbr class="cit-jnl-abbrev">J Natl Cancer Inst.</abbr> <span class="cit-pub-date">2005</span>;<span class="cit-vol">97</span>(<span class="cit-issue">17</span>):<span class="cit-fpage">1262</span>-<span class="cit-lpage">1271</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jnci&amp;resid=97/17/1262"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">26.</span><a class="rev-xref-ref" href="#xref-ref-26-1" title="View reference 26. in text"
                           id="ref-26">↵</a><div class="cit ref-cit ref-journal" id="cit-103.17.1299.26"
                             data-doi="10.1200/JCO.2007.14.0228">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Mamounas</span>  <span class="cit-name-given-names">EP</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Jeong</span>  <span class="cit-name-given-names">JH</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Wickerham</span>  <span class="cit-name-given-names">DL</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the
                                    National Surgical Adjuvant Breast And Bowel Project B-33 trial</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol.</abbr> <span class="cit-pub-date">2008</span>;<span class="cit-vol">26</span>(<span class="cit-issue">12</span>):<span class="cit-fpage">1965</span>-<span class="cit-lpage">1971</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=26/12/1965"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">27.</span><a class="rev-xref-ref" href="#xref-ref-27-1" title="View reference 27. in text"
                           id="ref-27">↵</a><div class="cit ref-cit ref-journal" id="cit-103.17.1299.27"
                             data-doi="10.1093/jnci/djm246">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Jakesz</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Greil</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Gnant</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian
                                    Breast and Colorectal Cancer Study Group Trial 6a</span>. <abbr class="cit-jnl-abbrev">J Natl Cancer Inst.</abbr> <span class="cit-pub-date">2007</span>;<span class="cit-vol">99</span>(<span class="cit-issue">24</span>):<span class="cit-fpage">1845</span>-<span class="cit-lpage">1853</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jnci&amp;resid=99/24/1845"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">28.</span><a class="rev-xref-ref" href="#xref-ref-28-1" title="View reference 28. in text"
                           id="ref-28">↵</a><div class="cit ref-cit ref-journal" id="cit-103.17.1299.28"
                             data-doi="10.1093/jnci/86.20.1534">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Love</span>  <span class="cit-name-given-names">RR</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Wiebe</span>  <span class="cit-name-given-names">DA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Feyzi</span>  <span class="cit-name-given-names">JM</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Newcomb</span>  <span class="cit-name-given-names">PA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Chappell</span>  <span class="cit-name-given-names">RJ</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment</span>. <abbr class="cit-jnl-abbrev">J Natl Cancer Inst.</abbr> <span class="cit-pub-date">1994</span>;<span class="cit-vol">86</span>(<span class="cit-issue">20</span>):<span class="cit-fpage">1534</span>-<span class="cit-lpage">1539</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jnci&amp;resid=86/20/1534"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">29.</span><a class="rev-xref-ref" href="#xref-ref-29-1" title="View reference 29. in text"
                           id="ref-29">↵</a><div class="cit ref-cit ref-journal" id="cit-103.17.1299.29">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Landi</span>  <span class="cit-name-given-names">G</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">D’Angelo</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Boccardi</span>  <span class="cit-name-given-names">E</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Hypercoagulability in acute stroke: prognostic significance</span>. <abbr class="cit-jnl-abbrev">Neurology.</abbr> <span class="cit-pub-date">1987</span>;<span class="cit-vol">37</span>(<span class="cit-issue">10</span>):<span class="cit-fpage">1667</span>-<span class="cit-lpage">1671</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=neurology&amp;resid=37/10/1667"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">30.</span><a class="rev-xref-ref" href="#xref-ref-30-1" title="View reference 30. in text"
                           id="ref-30">↵</a><div class="cit ref-cit ref-journal" id="cit-103.17.1299.30"
                             data-doi="10.1161/01.STR.21.8.1111">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Hart</span>  <span class="cit-name-given-names">RG</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Kanter</span>  <span class="cit-name-given-names">MC</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Hematologic disorders and ischemic stroke. A selective review</span>. <abbr class="cit-jnl-abbrev">Stroke.</abbr> <span class="cit-pub-date">1990</span>;<span class="cit-vol">21</span>(<span class="cit-issue">8</span>):<span class="cit-fpage">1111</span>-<span class="cit-lpage">1121</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=strokeaha&amp;resid=21/8/1111"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">31.</span><a class="rev-xref-ref" href="#xref-ref-31-1" title="View reference 31. in text"
                           id="ref-31">↵</a><div class="cit ref-cit ref-journal" id="cit-103.17.1299.31"
                             data-doi="10.1158/1538-7445.AM10-403">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ring</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Sestak</span>  <span class="cit-name-given-names">I</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Baum</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">The influences of co-morbidities and age on risk of death without recurrence: a retrospective analysis of the ATAC trial</span>. <abbr class="cit-jnl-abbrev">Cancer Res.</abbr> <span class="cit-pub-date">2010</span>;<span class="cit-vol">70</span> <span class="cit-supplement">24 suppl</span>:<span class="cit-fpage">403s</span>-<span class="cit-lpage">404s</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1158/1538-7445.AM10-403&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=The%20influences%20of%20co-morbidities%20and%20age%20on%20risk%20of%20death%20without%20recurrence%3A%20a%20retrospective%20analysis%20of%20the%20ATAC%20trial&amp;author=A%20Ring&amp;author=I%20Sestak&amp;author=M%20Baum&amp;publication_year=2010&amp;journal=Cancer%20Res.&amp;volume=70&amp;pages=403s-404s">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">32.</span><a class="rev-xref-ref" href="#xref-ref-32-1" title="View reference 32. in text"
                           id="ref-32">↵</a><div class="cit ref-cit ref-journal" id="cit-103.17.1299.32"
                             data-doi="10.1093/jnci/djq211">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Garber</span>  <span class="cit-name-given-names">JE</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Halabi</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Tolaney</span>  <span class="cit-name-given-names">SM</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer</span>. <abbr class="cit-jnl-abbrev">J Natl Cancer Inst.</abbr> <span class="cit-pub-date">2010</span>;<span class="cit-vol">102</span>(<span class="cit-issue">13</span>):<span class="cit-fpage">942</span>-<span class="cit-lpage">949</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jnci&amp;resid=102/13/942"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">33.</span><a class="rev-xref-ref" href="#xref-ref-33-1" title="View reference 33. in text"
                           id="ref-33">↵</a><div class="cit ref-cit ref-journal" id="cit-103.17.1299.33">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Liauw</span>  <span class="cit-name-given-names">WS</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Day</span>  <span class="cit-name-given-names">RO</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Adverse event reporting in clinical trials: room for improvement</span>. <abbr class="cit-jnl-abbrev">Med J Aust.</abbr> <span class="cit-pub-date">2003</span>;<span class="cit-vol">179</span>(<span class="cit-issue">8</span>):<span class="cit-fpage">426</span>-<span class="cit-lpage">428</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=14558867&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000186513800010&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Adverse%20event%20reporting%20in%20clinical%20trials%3A%20room%20for%20improvement&amp;author=WS%20Liauw&amp;author=RO%20Day&amp;publication_year=2003&amp;journal=Med%20J%20Aust.&amp;volume=179&amp;issue=8&amp;pages=426-428">Google Scholar</a></div>
                        </div>
                     </li>
                  </ol>
               </div><span class="highwire-journal-article-marker-end"></span></div>
            <div id="related">
               <h2>Related articles</h2>
               <ul class="related-list">
                  <div class="cit">
                     <div class="cit-metadata"><span class="cit-first-element cit-section">IN THIS ISSUE<span class="cit-sep cit-sep-after-article-section">:</span> </span><span class="cit-title">IN THIS ISSUE </span> <cite><abbr title="Journal of the National Cancer Institute" class="site-title">JNCI J Natl Cancer Inst</abbr> <span class="cit-print-date"><span class="cit-sep cit-sep-before-article-print-date">(</span>2011<span class="cit-sep cit-sep-after-article-print-date">)</span> </span><span class="cit-vol">103 </span><span class="cit-issue"><span class="cit-sep cit-sep-before-article-issue">(</span>17<span class="cit-sep cit-sep-after-article-issue">):</span> </span><span class="cit-pages"><span class="cit-first-page">1279</span> </span><span class="cit-doi"><span class="cit-sep cit-sep-before-article-doi"> doi:</span>10.1093/jnci/djr340 </span><span class="cit-online-date"><span class="cit-sep cit-sep-before-article-online-date">First published online </span>September 8, 2011 </span></cite>  
                     </div>
                     <div class="cit-extra"><span class="accesscheck jnci;103/17/1279 pdf_extract,full,reprint"></span> 
                        <ul class="cit-views">
                           <li class="first-item"><a href="/content/103/17/1279.extract" rel="extract">Extract</a></li>
                           <li><a href="/content/103/17/1279.full" rel="full-text">Full Text (HTML)</a></li>
                           <li class="last-item"><a href="/content/103/17/1279.full.pdf+html" rel="full-text.pdf">Full Text (PDF)</a></li>
                        </ul>  
                     </div> 
                  </div>
               </ul>
            </div><span id="related-urls"></span></div>
         <div id="col-2">
            
            <div class="article-nav sidebar-nav">
               <a href="/content/103/17/1292.short" title="Previous article" class="previous">« Previous</a><span class="article-nav-sep"> | </span><a href="/content/103/17/1310.short" title="Next article" class="next">Next Article »</a>
               
               <span class="toc-link">
                  				<a href="/content/103/17.toc" title="Table of Contents">Table of Contents</a>
                  			</span>
               
               
            </div>
            <div class="content-box" id="article-cb-main">
               <div class="cb-contents">
                  <h3 class="cb-contents-header"><span>This Article</span></h3>
                  <div class="cb-section cb-slug">
                     <ol>
                        <li>
                           <div id="slugline">
                              
                              <cite>
                                 <abbr title="JNCI Journal of the National Cancer Institute" class="slug-jnl-abbrev">
                                    <nlm:abbrev-journal-title xmlns:nlm="http://schema.highwire.org/NLM/Journal" abbrev-type="publisher">JNCI J Natl Cancer Inst</nlm:abbrev-journal-title></abbr><span class="slug-pub-date" itemprop="datePublished">
                                    (2011) 
                                    </span>
                                 
                                 <span class="slug-vol">
                                    103
                                    </span><span class="slug-issue">
                                    (17):
                                    </span><span class="slug-pages">
                                    1299-1309.
                                    </span>
                                 <span class="slug-doi-wrapper">
                                    
                                    doi:
                                    
                                    <span title="10.1093/jnci/djr242" class="slug-doi">10.1093/jnci/djr242</span>
                                    </span>
                                 </cite>
                              
                              
                              <span class="slug-metadata-note ahead-of-print">
                                 
                                 First published online
                                 
                                 <span class="slug-ahead-of-print-date">July 8, 2011</span>
                                 </span>
                              
                              
                              
                              
                              
                              
                              
                              
                              
                           </div>
                        </li>
                     </ol>
                  </div>
                  <div class="cb-section cb-views">
                     <ol>
                        <li class="abstract-view-link primary"><a href="/content/103/17/1299.abstract" rel="view-abstract">Abstract</a><span class="free">Free</span></li>
                        <li class="notice full-text-view-link"><span class="variant-indicator">» <span>Full Text (HTML)</span></span><span class="free">Free</span></li>
                        <li class="notice full-text-pdf-view-link"><a href="/content/103/17/1299.full.pdf+html" rel="view-full-text.pdf">Full Text (PDF)</a><span class="free">Free</span></li>
                        <li><a href="/content/103/17/1299/suppl/DC1" rel="supplemental-data"
                              class="dslink-supplementary-data">Supplementary Data</a></li>
                        <li class="cb-versions">
                           <div><span id="pap-all-versions-label">All Versions of this Article:</span><ol class="version-list">
                                 <li><a href="/content/early/2011/07/08/jnci.djr242.1">djr242v2</a></li>
                                 <li><a href="/content/early/2011/08/22/jnci.djr242">djr242v3</a></li>
                                 <li class="current-li"><span>103/17/1299</span> <span class="current-version">most recent</span></li>
                              </ol>
                           </div>
                        </li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-cat">
                     <h4 class="cb-section-header"><span>Classifications</span></h4>
                     <ol>
                        <li>
                           <ul class="subject-headings last-child">
                              <li><a class="tocsection-search"
                                    href="/search?tocsectionid=REVIEW&amp;sortspec=date&amp;submit=Submit">Review</a></li>
                           </ul>
                        </li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-svcs">
                     <h4 class="cb-section-header"><span>Services</span></h4>
                     <ol>
                        <li class="usage-stats-link icon-link"><a href="/articleusage?gca=jnci;103/17/1299" rel="nofollow">Article metrics</a></li>
                        <li class="alert-link icon-link"><a href="/cgi/alerts/ctalert?alertType=citedby&amp;addAlert=cited_by&amp;cited_by_criteria_resid=jnci%3B103%2F17%2F1299&amp;saveAlert=no&amp;return-type=article&amp;return_url=http://jnci.oxfordjournals.org/content/103/17/1299.full">Alert me when cited</a></li>
                        <li class="alert-link icon-link"><a href="/cgi/alerts/ctalert?alertType=correction&amp;addAlert=correction&amp;correction_criteria_value=103/17/1299&amp;saveAlert=no&amp;return-type=article&amp;return_url=http://jnci.oxfordjournals.org/content/103/17/1299.full">Alert me if corrected</a></li>
                        <li class="similar-link"><a href="/search?qbe=jnci%3Bdjr242&amp;citation=Amir%20et%20al.%20103%20%2817%29:%201299&amp;submit=yes">Find similar articles</a></li>
                        <li class="similar-link"><a href="/external-ref?access_num=jnci%3B103%2F17%2F1299&amp;link_type=ISI_RELATEDRECORDS"
                              id="cb-isi-similar-articles"
                              class="similar-link">Similar articles in Web of Science</a></li>
                        <li class="similar-link"><a href="/external-ref?access_num=21743022&amp;link_type=MED_NBRS"
                              class="similar-link">Similar articles in PubMed</a></li>
                        <li class="folder-link icon-link"><a href="/cgi/folders?action=addtofolder&amp;wherefrom=JOURNALS&amp;wrapped_id=jnci%3B103%2F17%2F1299">Add to my archive</a></li>
                        <li class="cit-man-link icon-link cite-link"><a href="/citmgr?gca=jnci%3B103%2F17%2F1299">Download citation</a></li>
                        <li><a class="request-permissions"
                              href="https://s100.copyright.com/AppDispatchServlet?publisherName=oup&amp;publication=jnci&amp;title=Toxicity%20of%20Adjuvant%20Endocrine%20Therapy%20in%20Postmenopausal%20Breast%20Cancer%20Patients%3A%20A%20Systematic%20Review%20and%20Meta-analysis%3A%20&amp;publicationDate=09%2F07%2F2011&amp;author=Eitan%20Amir%2C%20Bostjan%20Seruga%2C%20Saroj%20Niraula%2C%20Lindsay%20Carlsson%2C%20Alberto%20Oca%C3%B1a&amp;copyright=Oxford%20University%20Press&amp;contentID=10.1093%2Fjnci%2Fdjr242&amp;volumeNum=103&amp;issueNum=17&amp;startPage=1299&amp;endPage=1309&amp;orderBeanReset=true"
                              target="_blank">Request Permissions</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-cit">
                     <h4 class="cb-section-header"><span>Citing Articles</span></h4>
                     <ol>
                        <li class="hw-citing-link"><a href="/content/103/17/1299.full?cited-by=yes&amp;legid=jnci;103/17/1299#cited-by"
                              id="cb-hw-citing-articles">Load citing article information</a></li>
                        <li><a href="/cgi/crossref-forward-links/103/17/1299" rel="external-nw"
                              id="cb-crossref-citing-articles">Citing articles via CrossRef</a></li>
                        <li><a href="/scopus-links/jnci/103/17/1299?access_num=/jnci/103/17/1299"
                              rel="external-nw"
                              id="cb-scopus-citing-articles">Citing articles via Scopus</a></li>
                        <li><a href="/external-ref?access_num=%2Fjnci%2F103%2F17%2F1299&amp;link_type=ISI_CITING&amp;accnum_type=native"
                              rel="external-nw"
                              id="cb-isi-citing-articles">Citing articles via Web of Science</a></li>
                        <li><a href="/external-ref?access_num=http://jnci.oxfordjournals.org/content/103/17/1299.abstract&amp;link_type=GOOGLESCHOLAR">Citing articles via Google Scholar</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-gs">
                     <h4 class="cb-section-header"><span>Google Scholar</span></h4>
                     <ol>
                        <li class="cb-art-gs-auth author-link"><a href="http://scholar.google.com/scholar?q=%22author%3AAmir%20author%3AE.%22"
                              class="cb-art-gs-auth author-link">Articles by  Amir, E.</a></li>
                        <li class="cb-art-gs-auth author-link"><a href="http://scholar.google.com/scholar?q=%22author%3AOca%C3%B1a%20author%3AA.%22"
                              class="cb-art-gs-auth author-link">Articles by  Ocaña, A.</a></li>
                        <li class="cb-art-gs-rel similar-link"><a href="/external-ref?access_num=http://jnci.oxfordjournals.org/content/103/17/1299.abstract&amp;link_type=GOOGLESCHOLARRELATED">Search for related content</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-pm">
                     <h4 class="cb-section-header"><span>PubMed</span></h4>
                     <ol>
                        <li class="cb-art-pm-cite cite-link icon-link"><a href="/external-ref?access_num=21743022&amp;link_type=PUBMED"
                              class="cb-art-pm-cite cite-link icon-link">PubMed citation</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Amir%20E&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Amir, E.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Seruga%20B&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Seruga, B.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Niraula%20S&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Niraula, S.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Carlsson%20L&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Carlsson, L.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Oca%C3%B1a%20A&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Ocaña, A.</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-rel">
                     <h4 class="cb-section-header"><span>Related Content</span></h4>
                     <ol>
                        <li><a href="#related">Related articles in this journal</a></li>
                        <li><a href="/content/103/17/1299.full?related-urls=yes&amp;legid=jnci;103/17/1299#related-urls"
                              id="cb-related-urls">Load related web page information</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-soc">
                     <h4 class="cb-section-header"><span>Share</span></h4>
                     <ol>
                        <li><a href="/email?gca=jnci%3B103%2F17%2F1299&amp;current-view-path=/content/103/17/1299.full">
                              Email this article</a></li>
                        <li>
                           <div class="social-bookmarking">
                              
                              <ul class="social-bookmark-links">
                                 <li class="social-bookmarking-item social-bookmarking-item-citeulike"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/103/17/1299&amp;title=Toxicity%20of%20Adjuvant%20Endocrine%20Therapy%20in%20Postmenopausal%20Breast%20Cancer%20Patients%3A%20A%20Systematic%20Review%20and%20Meta-analysis+--+Amir%20et%20al.%20103%20%2817%29%3A%201299+--+jnci&amp;doi=10.1093/jnci/djr242&amp;link_type=CITEULIKE"><img src="/shared/img/common/social-bookmarking/citeulike.gif"
                                            alt="Add to CiteULike"
                                            title="CiteULike" /></a><span class="soc-bm-link-text">CiteULike</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-delicious"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/103/17/1299&amp;title=Toxicity%20of%20Adjuvant%20Endocrine%20Therapy%20in%20Postmenopausal%20Breast%20Cancer%20Patients%3A%20A%20Systematic%20Review%20and%20Meta-analysis+--+Amir%20et%20al.%20103%20%2817%29%3A%201299+--+jnci&amp;doi=10.1093/jnci/djr242&amp;link_type=DEL_ICIO_US"><img src="/shared/img/common/social-bookmarking/delicious.gif"
                                            alt="Add to Delicious"
                                            title="Delicious" /></a><span class="soc-bm-link-text">Delicious</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-facebook"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/short/103/17/1299&amp;title=Toxicity%20of%20Adjuvant%20Endocrine%20Therapy%20in%20Postmenopausal%20Breast%20Cancer%20Patients%3A%20A%20Systematic%20Review%20and%20Meta-analysis+--+Amir%20et%20al.%20103%20%2817%29%3A%201299+--+jnci&amp;doi=10.1093/jnci/djr242&amp;link_type=FACEBOOK"
                                       class="sb-facebook"
                                       rel="external-nw"><img src="/shared/img/common/social-bookmarking/facebook.gif" alt="Add to Facebook"
                                            title="Facebook" /></a><span class="soc-bm-link-text">Facebook</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-googleplus"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/103/17/1299&amp;title=Toxicity%20of%20Adjuvant%20Endocrine%20Therapy%20in%20Postmenopausal%20Breast%20Cancer%20Patients%3A%20A%20Systematic%20Review%20and%20Meta-analysis+--+Amir%20et%20al.%20103%20%2817%29%3A%201299+--+jnci&amp;doi=10.1093/jnci/djr242&amp;link_type=GOOGLEPLUS&amp;log_only=yes"><img src="/shared/img/common/social-bookmarking/googleplus.jpg" alt="Add to Google+"
                                            title="Google+" /></a><span class="soc-bm-link-text">Google+</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-mendeley"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/103/17/1299&amp;title=Toxicity%20of%20Adjuvant%20Endocrine%20Therapy%20in%20Postmenopausal%20Breast%20Cancer%20Patients%3A%20A%20Systematic%20Review%20and%20Meta-analysis+--+Amir%20et%20al.%20103%20%2817%29%3A%201299+--+jnci&amp;doi=10.1093/jnci/djr242&amp;link_type=MENDELEY"><img src="/shared/img/common/social-bookmarking/mendeley.gif" alt="Add to Mendeley"
                                            title="Mendeley" /></a><span class="soc-bm-link-text">Mendeley</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-twitter"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/103/17/1299&amp;title=Toxicity%20of%20Adjuvant%20Endocrine%20Therapy%20in%20Postmenopausal%20Breast%20Cancer%20Patients%3A%20A%20Systematic%20Review%20and%20Meta-analysis+--+Amir%20et%20al.%20103%20%2817%29%3A%201299+--+jnci&amp;doi=10.1093/jnci/djr242&amp;link_type=TWITTER"><img src="/shared/img/common/social-bookmarking/twitter.gif" alt="Add to Twitter"
                                            title="Twitter" /></a><span class="soc-bm-link-text">Twitter</span></li>
                              </ul>
                              
                              <p class="social-bookmarking-help"><a href="/help/social_bookmarks.dtl">What's this?</a></p>
                              
                           </div>
                        </li>
                     </ol>
                  </div>
               </div>
            </div>
            
            
            <div class="content-box" id="article-dyn-nav">
               <div class="cb-contents">
                  <h3 class="cb-contents-header"><span>Navigate This Article</span></h3>
                  <div class="cb-section" id="cb-art-nav">
                     <ol>
                        <li><a href="#content-block">Top</a></li>
                        <li><a href="#abstract-1">Abstract</a></li>
                        <li><a href="#sec-11">Methods</a></li>
                        <li><a href="#sec-16">Results</a></li>
                        <li><a href="#sec-25">Discussion</a></li>
                        <li><a href="#fn-group-1">Footnotes</a></li>
                        <li><a href="#ref-list-1">References</a></li>
                     </ol>
                  </div>
               </div>
            </div>
            
         </div>
         <div id="col-3">
            
            <div id="col-3-qs" class="sidebar-qs">
               
               
               <form class="searchbox" action="/search" method="get">
                  <p>Search this journal:</p>
                  <div>
                     	
                     	
                     	<input value="" type="text" name="fulltext" id="header-qs-input" />
                     <input type="hidden" name="submit" value="yes" />
                     
                     <input class="inline_button" type="image" alt="Go" src="/publisher/img/buttons/go.gif" />
                     
                     <div class="adv-search-link"><a href="/search">Advanced »</a></div>
                     
                     
                  </div>
               </form>
               
            </div>
            <div class="cb-contents">
               
               <div id="sidebar-current-issue" class="content-box">
                  	
                  <h3 class="cb-contents-header">Current Issue</h3>
                  	
                  <div class="cb-section">
                     	  
                     <ol>
                        <li>
                           	      <a href="/content/current"><span>
                                 		  <span class="current-issue-date">
                                    October 2015
                                    </span><span class="toc-citation-volume">
                                    
                                    107
                                    </span><span class="toc-citation-issue">(10)</span>
                                 		  
                                 		</span></a>
                           	    
                        </li>
                     </ol>
                     	
                  </div>
                  	
                  <div class="cb-section">
                     	  
                     <ol>
                        <li>
                           <a href="/content/current"><img src="/content/107/10.cover.gif" alt="JNCI J Natl Cancer Inst" id="cover" /></a>
                           
                        </li>
                     </ol>
                     	
                  </div>
                  	
                  <div class="cb-section sidebar-etoc-link">
                     	  
                     <ol>
                        <li><a href="/cgi/alerts/etoc">Alert me to new issues</a></li>
                     </ol>
                     	
                  </div>
                  
               </div>
               
            </div>
            
            <div id="second">
               
               <div class="ad_hidden" id="oas_right1">
                  <iframe id="id_advertframe_right1"
                          src="/resource/htmlfiles/advert.html?p=Right1&amp;u=jnci.oxfordjournals.org/content/103/17/1299.full"
                          width="0"
                          height="0"
                          frameborder="0"
                          scrolling="no"
                          class="resize_ad"></iframe>
                  
               </div>
               
               <div class="features">
                  
                  <div class="feature separator_after first">
                     
                     <h2 id="the_journal" title="The Journal"><span>The Journal</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/about.html" rel=""
                              title="About this journal">About this journal</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/contact_us.html" rel=""
                              title="Contact Us">Contact Us</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/access_purchase/rights_permissions.html"
                              rel=""
                              title="Rights &amp; Permissions">Rights &amp; Permissions</a>
                           
                        </li>
                        <li>
                           <a href="HTTP://www.oxfordjournals.org/access_purchase/dispatch_dates.html#JNCI.JP"
                              rel=""
                              title="Dispatch date of next issue">Dispatch date of next issue</a>
                           
                        </li>
                        <li>
                           <a href="http://publicationethics.org/" rel=""
                              title="This journal is a member of the Committee on Publication Ethics (COPE)">This journal is a member of the Committee on Publication Ethics (COPE)</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/mobile_faqs.html" rel=""
                              title="We are mobile – find out more">We are mobile – find out more</a>
                           
                        </li>
                        <li>
                           <a href="http://medicine-and-health-careernetwork.oxfordjournals.org/jobseeker/search/results/?t730=&amp;t732=469986&amp;t731=&amp;t733=&amp;t735=&amp;t737=&amp;max=25&amp;site_id=20102"
                              rel=""
                              title="Journals Career Network">Journals Career Network</a>
                           
                        </li>
                     </ul>
                     
                     <p>
                        <a href="http://www.oxfordjournals.org/our_journals/jnci/episodes_2012.html">
                           <img alt="Podcast Logo" style="float:left"
                                src="http://www.oxfordjournals.org/podcasts/podcast_icon_35x35.gif" />JNCI Podcast</a>
                        <br />
                        <br />
                        
                     </p>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Connect with us!</h3>
                     <a href="https://twitter.com/JNCI_Now">
                        <img class="small_margin" alt="Connect with us on Twitter!"
                             src="http://www.oxfordjournals.org/our_journals/phisci/connect_twitter.png"
                             style="vertical-align: top; float: left; " />
                        </a>
                     <a href="https://www.facebook.com/thejnci">
                        <img class="small_margin" alt="Connect with us on Facebook!"
                             src="http://www.oxfordjournals.org/our_journals/phisci/facebook.png"
                             style="vertical-align: top; float: left; " />
                        </a>
                     
                     <p>
                        <br />
                        <br />
                        
                     </p>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Editor-in-Chief</h3>
                     
                     <p>Carmen J. Allegra</p>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/editorial_board.html"
                              rel=""
                              title="View full editorial board">View full editorial board</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Impact factor: 12.583</h3>
                     
                     <h3 class="five_year">5-Yr impact factor: 13.584</h3>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h3>For the Media</h3>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/press_room.html" rel=""
                              title="JNCI PRESS ROOM">JNCI PRESS ROOM</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="for_authors" title="For Authors"><span>For Authors</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/for_authors/index.html"
                              rel=""
                              title="Instructions to authors">Instructions to authors</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/access_purchase/self-archiving_policyb.html"
                              rel=""
                              title="Self Archiving/Public Access Policy">Self Archiving/Public Access Policy</a>
                           
                        </li>
                     </ul>
                     <a href="http://www.oxfordjournals.org/oxfordopen/ ">
                        <img alt="Open access options for authors - visit Oxford Open"
                             src="http://www.oxfordjournals.org/resource/image/promos/oxford_open_small.gif" />
                        </a>
                     <a href="http://www.oxfordjournals.org/oxfordopen/funder_policies/">
                        <img alt="RCUK Wellcome Trust Open Access"
                             src="http://www.oxfordjournals.org/resource/image/wellcome-trust-180x100.jpg" />
                        </a>
                     
                     <p>Open access options for authors - visit <a href="http://www.oxfordjournals.org/oxfordopen/">Oxford Open</a>
                        
                     </p>
                     <a href="http://publicaccess.nih.gov/submit_process_journals.htm">
                        <img alt="PMC Logo" src="http://www.oxfordjournals.org/resource/image/pmc-logo.gif" />
                        </a>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://publicaccess.nih.gov/submit_process_journals.htm" rel=""
                              title="This journal enables compliance with the NIH Public Access Policy">This journal enables compliance with the NIH Public Access Policy</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="alerting_services" title="Alerting Services"><span>Alerting Services</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="/cgi/alerts/etoc" rel="" title="Email table of contents">Email table of contents</a>
                           
                        </li>
                        <li>
                           <a href="/cgi/alerts/etoc" rel="" title="Email Advance Access">Email Advance Access</a>
                           
                        </li>
                        <li>
                           <a href="http://jnci.oxfordjournals.org/help/citetrack/index.dtl" rel=""
                              title="CiteTrack">CiteTrack</a>
                           
                        </li>
                        <li>
                           <a href="/rss" rel="" title="XML RSS feed">XML RSS feed</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="corporate_services" title="Corporate Services"><span>Corporate Services</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/advertising.html" rel=""
                              title="Advertising sales">Advertising sales</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/reprints.html" rel=""
                              title="Reprints">Reprints</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/classifiedadinprint.html"
                              rel=""
                              title="Classified Advertising">Classified Advertising</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
               </div>
               <script type="text/javascript">var taxonomies = ["MED00300"];</script>
               </div>
            
            <div class="most-links-box js-marker">
               
               <div class="most-header">
                  
                  <h3>Most</h3>
                  
               </div>
               
               <ul>
                  <li class="most-cur-sel">
                     <h4>Most Read</h4>
                     	  
                     <div class="most-list">
                        	    
                        <ol>
                           <li class="first-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/92/6/443?rss=1&amp;ssource=mfr">Breast Density and Cancer Risk: What Is the Relationship?</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/90/9/713?rss=1&amp;ssource=mfr">The Female Prostate</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/91/14/1194?rss=1&amp;ssource=mfr">Tobacco Smoke Carcinogens and Lung Cancer</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/107/6/djv048?rss=1&amp;ssource=mfr">Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity,
                                 Poverty, and State</a></li>
                           <li class="last-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/105/23/1799?rss=1&amp;ssource=mfr">Elevated Plasma Vitamin B12 Levels as a Marker for Cancer: A Population-Based Cohort Study</a></li>
                        </ol>
                        	    <a href="http://jnci.oxfordjournals.org/reports/mfr1.dtl" class="view-all">» View all Most Read articles</a>
                        	  
                     </div>
                     	
                  </li>
                  <li>
                     <h4>Most Cited</h4>
                     	
                     <div class="most-list">
                        	  
                        <ol>
                           <li class="first-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/92/3/205?rss=1&amp;ssource=mfc">New Guidelines to Evaluate the Response to Treatment in Solid Tumors</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/90/18/1371?rss=1&amp;ssource=mfc">Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/85/5/365?rss=1&amp;ssource=mfc">The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International
                                 Clinical Trials in Oncology</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/82/13/1107?rss=1&amp;ssource=mfc">New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening</a></li>
                           <li class="last-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/82/1/4?rss=1&amp;ssource=mfc">What Is the Evidence That Tumors Are Angiogenesis Dependent?</a></li>
                        </ol>
                        	  <a href="http://jnci.oxfordjournals.org/reports/mfc1.dtl" class="view-all">» View all Most Cited articles</a>
                        	
                     </div>
                     
                  </li>
               </ul>
               
            </div>
            
            
            
         </div>
         
         
         
         <div id="oas_bottom" class="ad_hidden">
            <iframe id="id_advertframe_bottom"
                    src="/resource/htmlfiles/advert.html?p=Bottom&amp;u=jnci.oxfordjournals.org/content/103/17/1299.full"
                    width="0"
                    height="0"
                    frameborder="0"
                    scrolling="no"
                    class="resize_ad"></iframe>
            
         </div>
         
         
         
         
         
         
         <div id="secondary_footer">
            
            <div id="issn">Online ISSN 1460-2105 - Print ISSN 0027-8874</div>
            
            
            <div id="copyright"><a href="http://www.oxfordjournals.org/our_journals/terms.html">Copyright ©</a> 
               <span>2015</span> Oxford University Press
               
            </div>
            
         </div>
         
         <div id="primary_footer">
            
            <div id="site_logo">
               <strong><span>Oxford Journals</span></strong>
               <em><span>Oxford University Press</span></em>
               
            </div>
            
            
            <div id="third_nav">
               
               <ul>
                  <li><a href="http://www.oxfordjournals.org/site_map.html">Site Map</a></li>
                  <li><a href="http://www.oxfordjournals.org/legal/privacy_policy.html">Privacy Policy</a></li>
                  <li><a href="http://global.oup.com/cookiepolicy/?siteid=journals">Cookie Policy</a></li>
                  <li><a href="http://www.oxfordjournals.org/legal/legal_notices.html">Legal Notices</a></li>
                  <li><a href="http://www.oxfordjournals.org/faq/">Frequently Asked Questions</a></li>
               </ul>
               
            </div>
            
            
            <div id="other_oup_sites">
               
               <form action="http://www.oxfordjournals.org/service/redirect">
                  <div>
                     <label for="site_list">Other Oxford University Press sites:</label>
                     <select name="url" id="site_list">
                        <option value="http://www.oup.com">Oxford University Press</option>
                        <option value="http://www.oxfordjournals.org/china/">Oxford Journals China</option>
                        <option value="http://www.oxfordjournals.org/japan/">Oxford Journals Japan</option>
                        <option value="http://www.oup.com/uk/academic">Academic &amp; Professional books</option>
                        <option value="http://www.oup.com/oxed">Children's &amp; Schools Books</option>
                        <option value="http://www.oup.com/uk/dictionaries">Dictionaries &amp; Reference</option>
                        <option value="http://www.oup.co.uk/newdnb/">Dictionary of National Biography</option>
                        <option value="http://www.oup.com/uk/digital_reference">Digital Reference</option>
                        <option value="http://www.oup.com/elt/">English Language Teaching</option>
                        <option value="http://www.oup.com/uk/textbooks">Higher Education Textbooks</option>
                        <option value="http://www.oup.co.uk/ieu/">International Education Unit</option>
                        <option value="http://www.oup.com/uk/law">Law</option>
                        <option value="http://www.oup.com/uk/medicine">Medicine</option>
                        <option value="http://www.oup.com/uk/music">Music</option>
                        <option value="http://www.oup.com/online">Online Products &amp; Publishing</option>
                        <option value="http://oxfordbibliographiesonline.com">Oxford Bibliographies Online</option>
                        <option value="http://oxforddictionaries.com">Oxford Dictionaries Online</option>
                        <option value="http://www.oed.com">Oxford English Dictionary</option>
                        <option value="http://www.oxfordlanguagedictionaries.com">Oxford Language Dictionaries Online</option>
                        <option value="http://www.oxfordscholarship.com">Oxford Scholarship Online</option>
                        <option value="http://www.oup.com/uk/reference">Reference</option>
                        <option value="http://www.oup.com/uk/rights">Rights and Permissions</option>
                        <option value="http://www.oup.com/uk/booksellers">Resources for Retailers &amp; Wholesalers</option>
                        <option value="http://www.oup.com/uk/corporate">Resources for the Healthcare Industry</option>
                        <option value="http://www.oup.com/vsi">Very Short Introductions</option>
                        <option value="http://www.oup.com/worldsclassics">World's Classics</option></select>
                     
                     <input type="image" src="/resource/image/buttons/go.gif" alt="Go"
                            class="inline_button" />
                     
                  </div>
               </form>
               
            </div>
            
         </div>
         <script type="text/javascript"
                 src="http://gab.cookie.oup.com/aws-cookie/oup.cookiepolicy.pack.js"
                 defer="defer"></script>
         
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/jquery-ui.min.js"
                 type="text/javascript"></script>
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/jcarousellite.js"
                 type="text/javascript"></script>
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/pf_oiunderbarinit.js"
                 type="text/javascript"></script>
         <script defer="defer" src="/resource/js/underbar_local.js" type="text/javascript"></script>
         <script defer="defer" type="text/javascript">
    function fnc_onDomLoaded() {
        var query_context = getQueryContext();
        PF_initOIUnderbar(query_context,":QS:default","","JRN"); 
        PF_insertOIUnderbar(0);
    };
    if (window.addEventListener) { 
        window.addEventListener('load', fnc_onDomLoaded, false); 
    } else if (window.attachEvent) { 
        window.attachEvent('onload', fnc_onDomLoaded); 
    } 
</script>
         <noscript><img src="//ouptag.scholarlyiq.com/ntpagetag.gif?js=0" height="1" width="1"
                 border="0"
                 hspace="0"
                 vspace="0"
                 alt="" /></noscript><script type="text/javascript" src="//ouptag.scholarlyiq.com/ntpagetag.js"></script><script type="text/javascript">
        var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
        document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
        </script><script type="text/javascript">
        try {
        var pageTracker = _gat._getTracker("UA-189672-16");
        pageTracker._setDomainName(".oxfordjournals.org");
        pageTracker._trackPageview();
        } catch(err) {}
        </script></div>
   </body>
</html>